

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification FILED LOGGED	Admitted ENTERED RECEIVED
D0001	10/09/02		10/09/02 Letter from L. Stevens to M. Martinson		
D0002	10/14/02		10/14/02 Letter from L. Stevens to L. Frank		
D0003	10/15/02		10/15/02 Letter from L. Stevens to L. Frank		
D0004	10/18/02		10/18/02 Letter from L. Stevens to L. Frank		
D0005	10/22/02		10/22/02 Letter from L. Stevens to L. Frank		
D0006	10/29/02		10/29/02 Letter from L. Stevens to L. Frank		
D0007	11/14/02		11/14/02 Letter from L. Stevens to L. Frank with Attachments		
D0007	11/14/02		Attachment A to November 14, 2002 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0007	11/14/02		Attachment B to November 14, 2002 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0008	12/23/02		12/23/02 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0008	12/23/02		Attachment A to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment B to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment C to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment D to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment E to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment F to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment G to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment H to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment I to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment J to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment K to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment L to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment M to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0008	12/23/02		Attachment N to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0008	O	12/23/02	Attachment O to December 23, 2002 Letter from L. Stevens to L. Frank	APR 29 2011	APR 29 2011
D0009		02/28/03	02/28/03 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0009	A	02/28/03	Attachment A to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0009	B	02/28/03	Attachment B to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0009	C	02/28/03	Attachment C to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0009	D	02/28/03	Attachment D to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0009	E	02/28/03	Attachment E to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0009	F	02/28/03	Attachment F to February 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0010		03/28/03	03/28/03 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0010	A	03/28/03	Attachment A to March 28, 2003 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0010	B	03/28/03	Attachment B to March 28, 2003 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0011		04/28/03	04/28/03 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0011	A	04/28/03	Attachment A to April 28, 2003 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0011	B	04/28/03	Attachment B to April 28, 2003 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0011	C	04/28/03	Attachment C to April 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0011	D	04/28/03	Attachment D to April 28, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0012		05/21/03	05/21/03 Letter from L. Stevens to L. Frank with Attachments	APR 28 2011	APR 28 2011
D0012	A	05/21/03	Attachment A to May 21, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0012	B	05/21/03	Attachment B to May 21, 2003 Letter from L. Stevens to L. Frank	APR 28 2011	APR 28 2011
D0013		11/06/03	11/06/03 Letter from L. Stevens to R. Williams with Attachments	APR 28 2011	APR 28 2011
D0013	A	11/06/03	Attachment A to November 6, 2003 Letter from L. Stevens to R. Williams		
D0013	B	11/06/03	Attachment B to November 6, 2003 Letter from L. Stevens to R. Williams		
D0013	C	11/06/03	Attachment C to November 6, 2003 Letter from L. Stevens to R. Williams		
D0014			Summary Chart of 10/29/2002 Draft Letter		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0014	1	10/14/02	8:47 AM	Email from L. Stevens to D. Snyder, J. Murray, M. Brown, T. Thelen, ccd to S. Shade re: October 14, 2002. Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0014	2	10/14/02	2:24 PM	Email from M. Brown to D. Snyder, J. Murray, L. Stevens, S. Shade, T. Thelen, ccd to M. Brown re: October 14, 2002. Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0014	3	10/28/02	9:48 AM	Email from L. Stevens to J. Murray, T. Thelen, D. Snyder, M. Brown, ccd to S. Shade re: October 14, 2002. Attaching draft letter to L. Frank (FDA) from L. Stevens summarizing the document requests made by the FDA in a 10/25/02 conference call	
D0014	4	10/28/02	5:32 PM	Email from M. Jensen to L. Stevens, ccd to M. Brown re: FDA letter comments. Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with track changes)	
D0014	5	10/28/02	7:09 PM	Email from M. Jensen to N. Reeves re: FW: FDA letter comments. attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with track changes)	
D0014	6	10/29/02	3:51 AM	Email from T. Thelen to L. Stevens, ccd to J. Murray, D. Snyder, S. Shade, M. Brown re: FW: October 14, 2002. draft letter from L. Stevens to L. Frank	
D0014	7	10/29/02	12:47 PM	Email from L. Stevens to T. Thelen, S. Shade, D. Snyder, M. Brown, M. Jensen, J. Murray re: Final Review of Letter. Attaching draft letter to L. Frank (FDA) from L. Stevens summarizing the document requests made by the FDA in a 10/25/02 conference	
D0014	8	10/29/02	12:47 PM	Email from L. Stevens to T. Thelen, S. Shade, D. Snyder, M. Brown, M. Jensen, J. Murray re: Final Review of Letter. Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS	
D0014	9	10/29/02	2:43 PM	Email from J. Murray to L. Stevens, ccd to D. Snyder, M. Jensen, M. Brown, S. Shade, T. Thelen re: Re: Final Review of letter. Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0015				Summary Chart of 11/14/2002 Draft Letter	
D0015	1	11/04/02	3:59 PM	Email from S. Shade to L. Stevens re: Draft Response to #15. Attaching Draft FDA Request no. 15	
D0015	2	11/05/02	1:38 AM	Email from L. Stevens to J. Murray, M. Martinson, D. Clines, M. Jensen, M. Brown, T. Thelen, J. Modell, ccd to S. Shade and J. Lemieux. Attaching Draft Response to FDA Request no. 15 and slides	
D0015	3	11/07/02	8:23 AM	Email from D. Clines to L. Stevens, S. Shade, J. Modell, M. Martinson. Attaching Draft FDA Request no. 15	
D0015	4	11/07/02	8:55 AM	Email from S. Shade to L. Stevens re: Draft Letter. Attaching Draft November 8, 2002 Letter from L. Stevens to L. Frank	
D0015	5	11/07/02	10:50 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: Review Requested. Attaching Draft November 8, 2002 Letter from L. Stevens to L. Frank	MAY 3 2011
D0015	6	11/07/02	11:44 AM	Email from J. Modell to S. Shade re: Answers to your questions on speakers' training slides. Attaching Draft Comparative Slides and Draft FDA Request no. 15	
D0015	7	11/07/02	7:33 PM	Email from S. Shade to J. Lemieux re: save for me. Attaching Request no. 15	
D0015	8	11/08/02	12:00 PM	Draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0015	9	11/08/02	2:33 PM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: DRAFT 11/07/02. Attaching draft letter from L. Stevens to L. Frank	MAY 3 2011
D0015	10	11/11/02	4:03 PM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: DRAFT 11/07/02. Attaching draft letter from L. Stevens to L. Frank	MAY 3 2011
D0015	11	11/14/02		Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0016				Summary Chart of 12/23/2002 Letter	
D0016	1	12/12/02	7:44 AM	Email from S. Shade to L. Stevens re: Quest 14	
D0016	2	12/15/02	12:00 PM	Draft 12/15/02 Question 14	

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0016 3	12/15/02	12:01 PM	Email from S. Shade to M. Brown, M. Jensen, D. Snyder, T. Thelen, J. Lemieux, cc'd to L. Stevens re: Revised Draft Response to Quest. 14, Attaching Draft 12/17/02 Question 14		
D0016 4	12/15/02	12:02 PM	Draft 12/15/02 Question 14 (with handwritten notes)		
D0016 5	12/15/02	12:03 PM	Draft 12/15/02 Question 14		
D0016 6	12/15/02	6:47 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: Question 14, Attaching Draft 12/15/02 Question 14	MAY 3 2011	MAY 3 2011
D0016 7	12/15/02	6:47 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: Question 14, Attaching Draft 12/15/02 Question 14		
D0016 8	12/16/02	1:11 PM	Email from S. Shade to L. Stevens re: Question 14, Attaching Draft 12/15/02 Question 14		
D0016 9	12/17/02	3:04 PM	Email from L. Stevens to S. Shade re: FW: back to you, Attaching Draft 12/15/02 Question 14		
D0016 10	12/18/02	12:00 PM	12/18/02 Draft Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI) Sustained-Release Tablets MACMIS #11170 relating to Questions 12 and 14 (with track changes)		
D0016 11	12/18/02	2:33 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: Draft Letter Privileged/confidential, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens	MAY 3 2011	MAY 3 2011
D0016 12	12/18/02	2:51 PM	Email from S. Shade to L. Stevens re: FW: Quest 14, Attaching 12.11.02 draft Question 14 response		
D0016 13	12/18/02	5:35 PM	Email from M. Brown to L. Stevens and S. Shade, cc'd to M. Jensen, N. Reeves, T. Thelen, D. Snyder, D. Hanley, J. Lemieux re: Revised Response, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens	MAY 3 2011	MAY 3 2011
D0016 14	12/18/02	6:16 PM	Email from L. Stevens to M. Brown, M. Jensen, N. Reeves, cc'd to T. Thelen, D. Snyder, D. Hanley, J. Lemieux, S. Shade re: RE: Revised Response		
D0016 15	12/18/02	7:52 PM	Email from L. Stevens to S. Shade re: DRAFT 11/07/02, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens		
D0016 16	12/18/02	9:23 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: DRAFT 11/07/02 PRIVILEGED /CONFIDENTIAL, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens	MAY 3 2011	MAY 3 2011
D0016 17	12/18/02	9:54 PM	Email from S. Shade to E. Collins and A. Talton, cc'd to L. Stevens re: Draft Letter, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens		
D0016 18	12/18/02	9:57 PM	Email from S. Shade to D. Booth and D. Clines re: Draft Cover Letter, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens		
D0016 19	12/19/02	9:41 AM	Email from L. Stevens to M. Brown re: RE: DRAFT 11/07/02 PRIVILEGED/CONFIDENTIAL [sic]	MAY 3 2011	MAY 3 2011
D0016 20	12/19/02	10:24 AM	Email from E. Collins to S. Shade, cc'd to L. Stevens re: Draft Letter, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens		
D0016 21	12/19/02	11:40 AM	Email from M. Brown to S. Shade and L. Stevens, cc'd to D. Hanley, J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, D. Snyder, T. Thelen re: Revised Letter, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens	MAY 3 2011	MAY 3 2011
D0016 22	12/19/02	2:35 PM	Email from D. Clines to S. Shade and L. Stevens, cc'd to D. Booth and M. Milton re: RE: Draft Cover Letter, Attaching Draft 12/18/02 Letter to L. Frank from L. Stevens		
D0016 23	12/19/02	4:07 PM	Email from L. Stevens to N. Reeves and M. Brown, cc'd to J. Lemieux re: RE: DRAFT 11/07/02 PRIVILEGED/CONFIDENTIAL, Attaching Draft 12/19/02 Letter to L. Frank from L. Stevens (with track changes)	MAY 3 2011	MAY 3 2011
D0016 24	12/19/02	4:57 PM	Email from M. Brown to L. Stevens, cc'd to D. Snyder, T. Thelen, S. Shade, D. Hanley, J. Lemieux, M. Jensen, N. Reeves re: Latest Changes, Attaching Draft 12/19/02 Letter to L. Frank from L. Stevens (with track changes)		
D0016 25	12/19/02	4:58 PM	Email from M. Brown to L. Stevens, cc'd to D. Snyder, T. Thelen, S. Shade, D. Hanley, J. Lemieux, M. Jensen, N. Reeves re: Latest Changes, Attaching 12/19/02 draft letter from L. Stevens to L. Frank Re: NDA 20-358 Wellbutrin SR (bupropion HCI)		
D0016 26	12/19/02	4:58 PM	Email from M. Brown to L. Stevens, cc'd to D. Snyder, T. Thelen, S. Shade, D. Hanley, J. Lemieux, M. Jensen, N. Reeves re: Latest Changes, Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI) Sustained		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0016	27	5:16 PM	Email from L. Stevens to M. Brown, ccd to D. Snyder, T. Thelen, S. Shade, D. Hanley, J. Lemieux, M. Jensen, N. Reeves re: RE: Latest Changes		
D0016	28	7:23 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: RE: DRAFT 11/07/02 PRIVILEGED/CONFIDENTIAL, Attaching Draft 12/20/02 Letter to L. Frank from L. Stevens		
D0016	29	12:00 PM	Draft 12/20/02 Letter to L. Frank from L. Stevens (with handwritten notes)		
D0016	30	3:00 PM	Email from M. Brown to D. Hanley, J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder, L. Stevens, T. Thelen re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/SUBJECT TO WORK PRODU CT DOCTRINE	MAY 3 2011	MAY 3 2011
D0016	31	3:39 PM	Email from L. Stevens to M. Brown re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/SUBJECT TO WORK P RODU CT [sic] DOCTRINE		
D0016	32	1:21 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: FINAL LETTER, Attaching December 23, 2002 Letter from L. Stevens to L. Frank	MAY 3 2011	MAY 3 2011
D0016	33	1:22 PM	Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI) Sustained-Release Tablets MACMIS #11170		
D0016	34	3:19 PM	Email from M. Brown to L. Stevens re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/SUBJECT TO WORK PRODUCT DOCTRINE		
D0017			Summary Chart of 2/28/2003 Draft Letter		
D0017	1	12:24/02	Draft Response to DEA DDMAC Request Dated October 9, 2002		
D0017	2	12:30/02	December 12, 2002 Draft No. 2 of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017	3	12:31/02	Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017	4	12:31/02	Draft No. 1 of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017	5	12:00 PM	Draft GSK response to FDA Question 1		
D0017	6	12:01 PM	Draft GSK response to FDA Question 1		
D0017	7	01/16/03	Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017	8	01/19/03	Draft GSK response to FDA Question 1 (with notes inserted in text)		
D0017	9	12:00 PM	Draft GSK response to FDA Question 1 (with notes inserted in text)		
D0017	10	12:01 PM	Draft GSK response to FDA Question 1 (with track changes)		
D0017	11	12:02 PM	Draft GSK response to FDA Question 1 (with track changes)		
D0017	12	12:03 PM	Draft GSK response to FDA Question 1 (with handwritten notes)		
D0017	13	12:04 PM	Draft GSK response to FDA Question 1 (with typewritten and handwritten notes)		
D0017	14	12:05 PM	Draft GSK response to FDA Question 1 (with track changes and handwritten notes)		
D0017	15	12:06 PM	Draft GSK response to FDA Question 1 (with track changes and notes inserted in text)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017 16	01/22/03	2:14 PM	Email from N. Reeves to M. Brown and M. Jensen re: WBSR. Revised Anderson narrative attached; Attaching February 5, 2003 Draft Anderson Narrative	PLAY 3 2011	PLAY 3 2010
D0017 17	01/23/03	9:50 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes and handwritten notes)		
D0017 18	01/23/03	9:51 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 19	01/23/03	9:52 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 20	01/23/03	9:56 AM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, T. Thelen, J. Lemieux, ccd to M. Jensen and N. Reeves re: WBSR -- Draft Response Material; Attaching January 22, 2003 Draft GSK response to FDA Request 1	PLAY 3 2011	PLAY 3 2010
D0017 21	01/23/03	10:40 AM	Email from M. Brown to S. Shade, D. Snyder and L. Stevens, ccd to M. Jensen and N. Reeves re: Ryan & Anderson Drafts; Attaching Draft Ryan and Anderson Narratives		
D0017 22	01/25/03	10:45 AM	Draft of Dr. James Anderson Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 23	01/25/03	10:48 AM	Email from L. Stevens to S. Shade; Attaching January 22, 2003 Draft GSK response to FDA Request 1 (with track changes)		
D0017 24	01/25/03	11:06 AM	Email from L. Stevens to S. Shade re: PRIVILEGED/CONFIDENTIAL -ATTORNEY WORK PRODUCT; Attaching Draft Dr. Donna Ryan Narrative		
D0017 25	01/25/03	11:07 AM	Email from L. Stevens to S. Shade re: PRIVILEGED/CONFIDENTIAL -ATTORNEY WORK PRODUCT; Attaching Draft Dr. Donna Ryan Narrative (with handwritten notes)		
D0017 26	01/25/03	11:40 AM	Email from L. Stevens to S. Shade; Attaching Draft Anderson Narrative (with handwritten notes)		
D0017 27	01/25/03	11:40 AM	Email from L. Stevens to S. Shade; Attaching Draft Anderson Narrative (with handwritten notes)		
D0017 28	01/25/03	11:41 AM	Email from L. Stevens to S. Shade; Attaching Draft Anderson Narrative		
D0017 29	01/28/03	10:28 AM	Email from S. Shade to L. Stevens re: PRIVILEGED/CONFIDENTIAL -ATTORNEY WORK PRODUCT; Attaching Draft Dr. Donna Ryan Narrative (with track changes)		
D0017 30	01/29/03	8:23 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Donna Ryan Narrative; Attaching Draft Dr. Donna Ryan Narrative (with track changes)		
D0017 31	01/29/03	8:37 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Question 1; Attaching January 22, 2003 Draft GSK response to FDA Request 1 (with track changes)	PLAY 3 2011	PLAY 3 2010
D0017 32	01/30/03	10:00 AM	January 22, 2003 Draft GSK response to FDA Request 1 (with handwritten notes)		
D0017 33	01/30/03	10:04 AM	January 30, 2003 Fax from D. Snyder to D. Snyder re: PRIVILEGED & CONFIDENTIAL; Attaching January 23, 2003 GSK response to FDA Request 1 (with handwritten notes) and Dr. Donna Ryan Narrative		
D0017 34	01/30/03	2:27 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves; Attaching Draft Anderson Narrative (with track changes)		
D0017 35	01/31/03	11:00 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 36	01/31/03	11:01 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 37	01/31/03	11:02 AM	Draft of Dr. Donna Ryan Narrative; Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with handwritten notes)		
D0017 38	01/31/03	11:25 AM	Email from M. Jensen to L. Stevens and D. Snyder, ccd to S. Shade, T. Thelen, M. Brown, N. Reeves re: Revised Dr. Donna Ryan Narrative; Attaching Draft of Dr. Donna Ryan Narrative (with handwritten notes)		
D0017 39	01/31/03	11:53 AM	Email from S. Shade to M. Jensen re: RE: Revised Dr. Donna Ryan Narrative		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017 40	02/01/03	9:55 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Ryan narrative, Attaching Draft Dr. Donna Ryan Narrative (with track changes)		
D0017 41	02/01/03	9:55 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Ryan narrative, Attaching Draft Dr. Donna Ryan Narrative (with handwritten notes)		
D0017 42	02/05/03	9:56 AM	Drafts (February 5, 2003, two versions of January 23, 2003) of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with handwritten notes)		
D0017 43	02/05/03	9:57 AM	Draft GSK response to FDA Question 12		
D0017 44	02/05/03	9:58 AM	Draft GSK response to FDA Question 12 (with track changes)		
D0017 45	02/05/03	9:59 AM	Draft GSK response to FDA Question 12		
D0017 46	02/05/03	10:00 AM	Draft GSK response to FDA Question 12 (with handwritten notes)		
D0017 47	02/05/03	10:01 AM	Draft GSK response to FDA Question 12 (with handwritten notes)		
D0017 48	02/05/03	10:02 AM	Email from N. Reeves to M. Brown, ccd to M. Jensen re: GSK WBSR revised response to question 12, Attaching revised response to FDA Question 12	MAY 3 2011	MAY 3 2011
D0017 49	02/05/03	2:41 PM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: Dr. Ryan Narrative, Attaching blackline of revised response to FDA Request 1	MAY 3 2011	MAY 3 2011
D0017 50	02/05/03	2:42 PM	Email S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: Dr. Ryan Narrative, Attaching Draft Dr. Donna Ryan Narrative (with track changes)		
D0017 51	02/05/03	4:42 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Response to WBSR Q. 12, Attaching draft response to FDA Question 12 (with handwritten notes)		
D0017 52	02/05/03	4:42 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Response to WBSR Q. 12, Attaching draft response to FDA Question 12 (with handwritten notes)		
D0017 53	02/05/03	4:42 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Response to WBSR Q. 12, Attaching draft response to FDA Question 12		
D0017 54	02/05/03	4:42 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux re: Response to WBSR Q. 12, Attaching draft GSK response to FDA Question 12		
D0017 55	02/06/03	1:59 PM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade re: FW: Dr. Ryan Narrative, Attaching draft Dr. Donna Ryan Narrative (with track changes)		
D0017 56	02/06/03	4:58 PM	Email from L. Stevens to M. Jensen, ccd to M. Brown re: RE: Dr. Ryan Transcript		
D0017 57	02/10/03	5:00 PM	Draft GSK response to FDA Question 12 (with handwritten notes)		
D0017 58	02/10/03	5:16 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves, M. Jensen, J. Lemieux re: Revised Dr. Anderson Narrative, Attaching draft Anderson Narrative		
D0017 59	02/10/03	5:17 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves, M. Jensen, J. Lemieux re: Revised Dr. Anderson Narrative, Attaching draft Anderson Narrative (with handwritten notes)		
D0017 60	02/10/03	6:00 PM	Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 61	02/10/03	6:01 PM	February 11, 2003 and February 12, 2003 Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes and handwritten notes) *several versions; draft February		
D0017 62	02/11/03	11:00 AM	Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017 63	02/11/03	11:01 AM	Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with handwritten notes)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017	64	02/11/03	11:02 AM	Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (blackline with handwritten notes)	
D0017	65	02/11/03	11:03 AM	Draft GSK response to FDA Question 12 (with handwritten notes)	
D0017	66	02/11/03	11:04 AM	Draft GSK response to FDA Question 12 (with handwritten notes)	
D0017	67	02/11/03	11:05 AM	Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (blackline with handwritten notes)	
D0017	68	02/11/03	11:46 AM	Email from M. Brown to S. Shade, D. Snyder and L. Stevens, cc'd to M. Jensen and N. Reeves re: Response to Request No. 12, Attaching draft GSK response to FDA Question 12	
D0017	69	02/11/03	11:55 AM	Email from M. Jensen to L. Stevens, S. Shade, D. Snyder, cc'd to M. Brown, N. Reeves re: Revised Ryan Narrative, Attaching draft Dr. Donna Ryan Narrative (with track changes)	
D0017	70	02/11/03	11:55 AM	Email from M. Jensen to L. Stevens, S. Shade, D. Snyder, cc'd to M. Brown, N. Reeves re: Revised Ryan Narrative, Attaching blackline of draft Dr. Donna Ryan Narrative	
D0017	71	02/11/03	12:06 PM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, cc'd to M. Jensen, N. Reeves re: Response No. 12, Attaching draft GSK response to FDA Question 12	
D0017	72	02/11/03	12:21 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT, Attaching draft Anderson	
D0017	73	02/11/03	12:34 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Ryan Narrative PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT, Attaching draft Dr. Donna	
D0017	74	02/11/03	12:34 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Ryan Narrative PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT, Attaching draft Dr. Donna	
D0017	75	02/11/03	12:39 PM	Email from L. Stevens, M. Brown, J. Hetzel, J. Lemieux, M. Jensen, N. Reeves, S. Shade, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL, ATTORNEY WORK PRODUCT, Attaching draft GSK	
D0017	76	02/11/03	12:44 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL, ATTORNEY WORK PRODUCT, Attaching draft GSK response to FDA Question 12 (with	
D0017	77	02/11/03	12:44 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL, ATTORNEY WORK PRODUCT, Attaching draft GSK response to FDA Question 12 (with	
D0017	78	02/11/03	1:58 PM	Email from J. Lemieux to L. Stevens, J. Hetzel, S. Shade re: RE: PRIVILEGED/CONFIDENTIAL, ATTORNEY WORK PRODUCT	
D0017	79	02/11/03	8:43 PM	Email from S. Shade to J. Lemieux re: RE: PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT	
D0017	80	02/12/03	12:00 PM	Unsigned Letter from M. Brown to D. Anderson re: GlaxoSmithKline Response to FDA Inquiry and Unsigned Letter from M. Brown to O. Wolkowitz re: GlaxoSmithKline Response to FDA Inquiry	
D0017	81	02/12/03	12:01 PM	Draft GSK response to FDA Question 12 (with track changes)	
D0017	82	02/12/03	12:02 PM	Draft GSK response to FDA Question 1 (with track changes)	
D0017	83	02/12/03	12:03 PM	Letter from M. Brown to D. Ryan re: GlaxoSmithKline Response to FDA Inquiry	
D0017	84	02/12/03	12:04 PM	Signed Letter from M. Brown to D. Anderson re: GlaxoSmithKline Response to FDA Inquiry and attached Presentation materials from American Diabetes Association	
D0017	85	02/12/03	12:05 PM	Draft GSK response to FDA Question 1 (with handwritten notes)	
D0017	86	02/12/03	12:06 PM	Draft GSK response to FDA Question 1 (with blackline edits handwritten notes)	
D0017	87	02/12/03	12:07 PM	Draft GSK response to FDA Question 1 (with blackline edits handwritten notes)	

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
DD0017 88	02/12/03	12:08 PM	Fax from M. Jensen to L. Stevens, S. Shade, D. Snyder, Attaching Signed Letter from M. Brown to Dr. Ryan re: GlaxoSmithKline Response to DFA Inquiry		
DD0017 89	02/12/03	12:09 PM	Fax from M. Jensen to D. Ryan, Attaching Signed Letter from M. Brown to Dr. Ryan re: GlaxoSmithKline Response to DFA Inquiry		
DD0017 90	02/12/03	4:35 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves and M. Jensen re: Response to Request No. 1; Attaching Draft GSK response to FDA Question 1 (with track changes)	MAY 3 2011	MAY 3 2011
DD0017 91	02/12/03	4:35 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves and M. Jensen re: Response to Request No. 1; Attaching Draft GSK response to FDA Question 1 (with handwritten notes)		
DD0017 92	02/12/03	5:30 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves, ccd to L. Stevens, S. Shade re: RE: Speaker Utilization, Attaching Draft GSK response to FDA Question 1 (with blackline edits handwritten notes)		
DD0017 93	02/12/03	6:31 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Jensen and N. Reeves re: Response No. 12; Attaching draft response to FDA Question 12 (blackline)		
DD0017 94	02/12/03	6:31 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Jensen and N. Reeves re: Response No. 12; Attaching draft response to FDA Question 12 (with track changes)		
DD0017 95	02/12/03	6:31 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Jensen and N. Reeves re: Response No. 12; Attaching draft response to FDA Question 12 (with track changes and handwritten notes)		
DD0017 96	02/12/03	9:44 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Privileged/confidential Attorney Work Product, Attaching draft response to FDA Question 12 (with track changes)		
DD0017 97	02/12/03	10:52 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, re: Question 1, Attaching draft response to FDA Request 1 (blackline with handwritten notes)		
DD0017 98	02/12/03	10:53 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Question 1, Attaching draft response to FDA Request 1 (with track changes)	MAY 3 2011	MAY 3 2011
DD0017 99	02/13/03	2:55 PM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: Question 1; Attaching draft response to FDA Request 1 (with track changes and handwritten notes)		
DD0017 100	02/13/03	2:56 PM	Email from M. Brown to D. Snyder re: FW: Question 1, Attaching draft response to FDA Request 1 (blackline)	MAY 3 2011	MAY 3 2011
DD0017 101	02/14/03	12:00 PM	February 14, 2003 Draft No. 2 of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
DD0017 102	02/14/03	12:01 PM	February 14, 2003 Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
DD0017 103	02/14/03	12:10 PM	Email from M. Brown to D. Snyder, S. Shade, L. Stevens, ccd to M. Jensen and N. Reeves re: Request No. 1 - Revised Response, Attaching draft response to FDA Request 1 (blackline)	MAY 3 2011	MAY 3 2011
DD0017 104	02/14/03	1:43 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Question 1 PRIVILEGED/CONFIDENTIAL ATTORNEY WORK PRODUCT, Attaching draft response to Request No. 1 (with blackline)		
DD0017 105	02/14/03	1:43 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Question 1 PRIVILEGED/CONFIDENTIAL ATTORNEY WORK PRODUCT, Attaching draft GSK response to FDA Question 1		
DD0017 106	02/14/03	1:59 PM	Email from L. Stevens to M. Brown, J. Hetzel, J. Lemieux, M. Jensen, N. Reeves, S. Shade, D. Snyder re: RE: Question 1 PRIVILEGED/CONFIDENTIAL ATTORNEY WORK PRODUCT, Attaching draft GSK response to FDA Question 1 (with		
DD0017 107	02/14/03	2:58 PM	Fax from M. Jensen to D. Ryan, Attaching Draft of Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
DD0017 108	02/14/03	5:30 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION ATTORNEY WORK PRODUCT, Attaching draft GSK		
DD0017 109	02/18/03	10:21 AM	Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
DD0017 110	02/18/03	10:21 AM	Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
DD0017 111	02/18/03	10:21 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION ATTORNEY WORK PRODUCT, Attaching draft GSK		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017 112	02/18/03	10:21 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION ATTORNEY WORK PRODUCT. Attaching draft GSK		
D0017 113	02/19/03	12:00 PM	Draft GSK response to FDA Question 1 (blackline)		
D0017 114	02/19/03	12:01 PM	Draft GSK response to FDA Question 1 (blackline with handwritten notes)		
D0017 115	02/19/03	12:02 PM	Draft GSK response to FDA Question 1		
D0017 116	02/19/03	12:03 PM	Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017 117	02/19/03	2:23 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Request No. Attaching draft GSK response to FDA Question 1 (with track changes)		
D0017 118	02/19/03	4:23 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown and J. Lemieux re: Ryan Narrative. Attaching Draft of Dr. Donna Ryan Narrative		
D0017 119	02/19/03	5:29 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Jensen, N. Reeves re: Revised Response to Request No. 12. Attaching draft GSK response to FDA Request 12		
D0017 120	02/19/03	7:01 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, ccd to M. Jensen, N. Reeves, J. Lemieux re: Request No. 1. Attaching draft GSK response to FDA Request 1 (with track changes)	MAY 3 2011	MAY 3 2011
D0017 121	02/19/03	7:21 PM	Email from N. Reeves to M. Brown re: RE: Revised Anderson narrative		
D0017 122	02/20/03	8:30 AM	February 20, 2003 Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017 123	02/20/03	8:33 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Question 1. Attaching Draft GSK response to FDA Request 1 (with track changes)	MAY 3 2011	MAY 3 2011
D0017 124	02/20/03	8:35 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: Question 1. Attaching Draft GSK response to FDA Request 1 (with track changes)		
D0017 125	02/20/03	8:49 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION. Attaching Draft GSK response to FDA Request 1 (with track changes)		
D0017 126	02/20/03	8:49 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION. Attaching Draft GSK response to FDA Request 1		
D0017 127	02/20/03	9:26 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Ryan Narrative. Attaching Dr. Donna Ryan Narrative (with track changes)		
D0017 128	02/20/03	11:41 AM	Email from S. Shade to J. Millar, ccd to S. Hull, D. Guterman, L. Stevens re: FDA Request No. 1- PRIVILEGED AND CONFIDENTIAL/ATTORNEY WORK PRODUCT. Attaching Draft GSK response to FDA Request 1	MAY 3 2011	MAY 3 2011
D0017 129	02/20/03	11:43 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: Question 1. Attaching Draft GSK response to FDA Request 1 (with track changes)		
D0017 130	02/20/03	11:43 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Question 1. Attaching Draft GSK response to FDA Request 1 (with track changes)		
D0017 131	02/20/03	11:43 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: Question 1. Attaching Draft GSK response to FDA Request 1 (blackline with handwritten notes)	MAY 5 2011	MAY 5 2011
D0017 132	02/20/03	12:23 PM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: Dr. Ryan Narrative. Attaching draft Dr. Donna Ryan Narrative (blackline with handwritten notes)		
D0017 133	02/20/03	3:07 PM	Email from J. Lemieux to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: Question # 12 PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION. Attaching Draft GSK response to FDA Request 12 (with track changes)		
D0017 134	02/20/03	3:11 PM	PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION		
D0017 135	02/20/03	3:38 PM	Email from L. Stevens to M. Jensen, J. Lemieux, J. Hetzel, M. Brown, S. Shade, D. Snyder re: RE: Question # 12 PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017	136	02/20/03	4:01 PM	Email from N. Reeves to L. Stevens, S. Shade, J. Hetzel, D. Snyder, J. Lemieux, ccd to M. Brown, M. Jensen re: Revised narrative for Dr. Anderson attached. Attaching February 20, 2003 Anderson narrative with handwritten notes	
D0017	137	02/21/03	1:28 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching February 21, 2003 Anderson Narrative (with track	
D0017	138	02/21/03	2:55 PM	Email from M. Jensen to L. Stevens, J. Hetzel, J. Lemieux, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION	
D0017	139	02/23/03	5:56 PM	Email from N. Reeves to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder re: FW: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching February 25, 2003 Draft Anderson Narrative	
D0017	140	02/23/03	11:30 PM	Email from L. Stevens to M. Brown, D. Snyder, M. Jensen, J. Hetzel, J. Lemieux, N. Reeves, S. Shade re: FW: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION	
D0017	141	02/24/03	12:23 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel re: Final Dr. Ryan Narrative; Attaching February 24, 2003 draft of Dr. Ryan Narrative	
D0017	142	02/24/03	3:15 PM	Email from N. Reeves to M. Brown, ccd to M. Jensen re: Revised Anderson attached for your review (408352 v. 6). Attaching February 25, 2003 Anderson narrative (with track changes and handwritten notes)	
D0017	143	02/25/03	7:28 AM	Email from S. Shade to D. Snyder, J. Hetzel, J. Lemieux, L. Stevens, M. Jensen, M. Brown, N. Reeves re: FW: FDA Request No. 1 - PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Draft GSK response to FDA Request 1	
D0017	144	02/25/03	7:28 AM	Email from S. Shade to D. Snyder, J. Hetzel, J. Lemieux, L. Stevens, M. Jensen, M. Brown, N. Reeves re: FW: FDA Request No. 1 - PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Draft GSK response to FDA Request 1	
D0017	145	02/25/03	12:00 PM	Draft GSK response to FDA Question 1 (with track changes)	
D0017	146	02/25/03	12:01 PM	February 25, 2003 Draft letter from L. Stevens to L. Frank (with track changes)	
D0017	147	02/25/03	3:03 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves, M. Jensen re: Anderson -- Revised Draft; Attaching February 25, 2003 Draft Anderson Narrative (with track changes)	
D0017	148	02/25/03	4:29 PM	Email from M. Jensen to M. Brown, ccd to N. Reeves re: RE: Question # 12 PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION	PLAT 3 2011
D0017	149	02/25/03	5:49 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux ccd to M. Brown, N. Reeves re: Final Q. 12; Attaching draft GSK response to FDA Question 12	PLAT 3 2011
D0017	150	02/25/03	5:49 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Final Q. 12; Attaching GSK response to FDA Request 12 (blackline)	
D0017	151	02/25/03	6:06 PM	Email from M. Brown to L. Stevens re: RE: Anderson -- Revised Draft	
D0017	152	02/25/03	6:53 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Consolidated FDA Response # 3; Attaching Consolidated Draft FDA Response #3	
D0017	153	02/25/03	7:08 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to M. Jensen, N. Reeves re: Revised Request No. 1 - Response; Attaching February 25, 2003 Draft Anderson Narrative (with track changes)	
D0017	154	02/25/03	11:05 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Consolidated Draft FDA Response #3 (with track changes)	
D0017	155	02/25/03	11:05 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Consolidated Draft FDA Response #3 (with handwritten notes)	
D0017	156	02/25/03	11:28 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Draft GSK response to FDA Request 1 (with track changes)	
D0017	157	02/26/03	8:30 AM	February 26, 2003 Revised Consolidated Draft FDA Response #3	
D0017	158	02/26/03	8:40 AM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Draft GSK response to FDA Request 1 (with track changes)	
D0017	159	02/26/03	9:02 AM	Email from S. Shade to D. Snyder, J. Hetzel, J. Lemieux, L. Stevens, M. Jensen, M. Brown, N. Reeves re: PRIVILEGED AND CONFIDENTIAL /ATTORNEY WORK PRODUCT; Attaching Consolidated Draft FDA Response #3 (with track changes)	

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0017 160	02/26/03	9:30 AM	Draft Dr. Donna Ryan Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13		
D0017 161	02/26/03	9:31 AM	Email from S. Shade to M. Jensen, L. Stevens, D. Snyder, J. Lemieux, ccd to M. Brown, N. Reeves re: RE: Final Q.12; Attaching Draft GSK response to FDA Request 12 (with track changes)		
D0017 162	02/26/03	9:35 AM	Email from M. Brown to M. Jensen, J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to N. Reeves re: RE: Final Q.12		
D0017 163	02/26/03	12:00 PM	Various November 11, 2007 Drafts of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 164	02/26/03	12:01 PM	November 11, 2007 Draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 165	02/26/03	12:02 PM	Final November 11, 2007 draft of Dr. James Anderson Narrative, Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5, 6, 7, 8, 9, 10, 13 (with track changes)		
D0017 166	02/26/03		Memorandum from M. Jensen to L. Stevens and S. Shade, ccd to M. Brown and N. Reeves re: Dr. Anderson & Ryan Narratives, Copies of Additional Attachments		
D0017 167	02/27/03	12:46 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Revised Consolidated FDA Response # 3; Attaching Consolidated Draft FDA Response #3 (blackline)		
D0017 168	02/27/03	6:53 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Jensen, N. Reeves re: Final Consolidated Supp. Response; Attaching February 28, 2003 Letter from L. Stevens to L. Frank	MAY 3 2011	MAY 3 2011
D0017 169	02/28/03	7:52 AM	Email from L. Stevens to M. Brown re: RE: Final Consolidated Supp. Response		
D0017 170	02/28/03	8:00 AM	February 28, 2003 Letter from L. Stevens to L. Frank with handwritten notes		
D0017 171	02/28/03	8:01 AM	Signed February 28, 2003 Letter from L. Stevens to L. Frank		
D0018			Summary Chart of 3/28/03 Draft Letter		
D0018 1	03/11/03	9:46 AM	Email from N. Reeves to L. Stevens, S. Shade, D. Snyder, J. Lemieux, ccd to M. Brown, M. Jensen re: Wellbutrin Investigation; Draft narrative re: speaker databases attached; Attaching draft GSK response to FDA Questions 3, 7, and 8	MAY 6 2011	MAY 6 2011
D0018 2	03/12/03	1:45 PM	Email from S. Shade to N. Reeves, L. Stevens, D. Snyder, J. Lemieux, ccd to M. Brown, M. Jensen re: RE: Wellbutrin Investigation; Draft narrative re: speaker databases attached; Attaching draft GSK response to FDA Questions 3, 7, and 8 (with draft GSK response to FDA Questions 3, 7, and 8	MAY 9 2011	MAY 9 2011
D0018 3	03/12/03	1:57 PM	Email from S. Shade to J. Lemieux re: FW: Wellbutrin Investigation; Draft narrative re: speaker databases attached; Attaching draft GSK response to FDA Questions 3, 7, and 8		
D0018 4	03/12/03	7:22 PM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Brown, N. Reeves re: Speaker Database Comments; Attaching blackline of draft GSK response to FDA Questions 3, 7, and 8	MAY 6 2011	MAY 9 2011
D0018 5	03/12/03	7:31 PM	Draft GSK responses to FDA Questions 3, 7, and 8 (one containing track changes) and Draft GSK supplemental response to FDA Question 14		
D0018 6	03/13/03	10:17 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching draft GSK response to FDA Questions 3, 7, and 8	MAY 6 2011	MAY 6 2011
D0018 7	03/14/03	12:00 PM	Draft GSK response to FDA Questions 3, 7, and 8 (with track changes and handwritten notes)		
D0018 8	03/14/03	12:01 PM	Draft GSK response to FDA Questions 3, 7, and 8 (with handwritten notes)		
D0018 9	03/18/03	12:17 PM	Email from M. Brown to L. Stevens, ccd to M. Jensen, N. Reeves re: RE: [no subject]		
D0018 10	03/18/03	1:05 PM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, M. Brown, N. Reeves re: Revised Database Narrative; Attaching draft GSK response to FDA Questions 3, 7, and 8	MAY 6 2011	MAY 6 2011
D0018 11	03/19/03	12:00 PM	Draft GSK response to FDA Questions 3, 7, and 8 (with handwritten notes)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0018	12	03/19/03	12:01 PM	Draft GSK response to FDA Questions 3, 7, and 8 (with handwritten notes)	
D0018	13	03/21/03	3:59 PM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Brown, N. Reeves re: Revised Response re: Speaker Spreadsheets; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release	MAY 6 2011
D0018	14	03/21/03	4:00 PM	Draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0018	15	03/21/03	5:06 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: PRIVILEGED/CONFIDENTIAL; Attaching blackline of draft letter to L. Frank containing GSK response to FDA Questions 3,	MAY 6 2011
D0018	16	03/21/03	6:07 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL; Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion	MAY 6 2011
D0018	17	03/22/03	12:00 PM	Draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with track changes and handwritten notes)	
D0018	18	03/26/03	3:01 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel re: Revised FDA Response re: Spreadsheets; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	MAY 6 2011
D0018	19	03/26/03	3:20 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel, ccd to M. Brown, N. Reeves re: Final FDA	MAY 6 2011
D0018	20	03/26/03	3:23 PM	Response re: Spreadsheets; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release	
D0018	21	03/26/03	3:31 PM	Email from D. Snyder to L. Stevens, ccd to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin	MAY 6 2011
D0018	22	03/26/03	4:00 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, S. Shade re: RE: Revised FDA Response re: Spreadsheets	
D0018	23	03/26/03	4:01 PM	Draft Letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 and Draft GSK responses to FDA Questions 3, 7, and 8 (with track changes and handwritten notes)	
D0018	24	03/26/03	4:10 PM	Draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	
D0018	25	03/26/03	6:42 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching draft letter from L. Stevens to L. Frank re: NDA 20-	MAY 6 2011
D0018	26	03/26/03	6:53 PM	Email from S. Shade to M. Jensen, L. Stevens, D. Snyder, J. Lemieux, J. Hetzel, ccd to M. Brown, N. Reeves re: Final FDA	MAY 6 2011
D0018	27	03/27/03	11:00 AM	Response re: Spreadsheets; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release	MAY 6 2011
D0018	28	03/27/03	11:30 AM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel, ccd to M. Brown, N. Reeves re: FDA-ready	
D0018	29	03/28/03	12:00 PM	Version of Response re: Spreadsheets; Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl)	
D0018	30	03/28/03		Email from L. Stevens to J. Lemieux, ccd to S. Shade re: privileged/confidential	
D0018	31	03/28/03	12:01 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves re: Revised Response to Speaker Spreadsheets; Attaching Blackline of draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-	
D0019				Draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0019				Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
D0019				Summary Chart of 04/28/2003 Draft Letter	
D0019	1	03/04/03	5:31 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: SE Database Rev4 - 03	
D0019	2	03/29/03	12:00 PM	04 03.xls; Attaching GlaxoSmithKline Speaker Event Database - Wellbutrin SR - 2001-2002	
D0019	3	03/29/03	12:01 PM	Draft Wolkowitz Narrative	
D0019				Draft Wolkowitz Narrative	

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0019 4	04/03/03	6:23 PM	Email from N. Reeves to L. Stevens, S. Shade, ccd to M. Brown, M. Jensen re: Draft narrative for Dr. Wolkowitz attached.		
D0019 5	04/09/03	9:05 AM	Attaching draft Wolkowitz Narrative Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: PRIVILEGED/CONFIDENTIAL, LEGAL, COMMUNICATION, Attaching Draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 6	04/09/03	9:06 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL, LEGAL, COMMUNICATION, Attaching Draft Wolkowitz Narrative (with handwritten notes)		
D0019 7	04/09/03	12:36 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: GSK's Supplemental Response to Question No. 14	MAY 6 2011	MAY 6 2011
D0019 8	04/09/03	10:16 PM	Email from N. Reeves to M. Brown, ccd to M. Jensen re: GSK WBSR: revised draft narrative for Wolkowitz	MAY 6 2011	MAY 6 2011
D0019 9	04/09/03	11:00 PM	Blackline of draft Wolkowitz Narrative		
D0019 10	04/09/03	11:01 PM	Draft Wolkowitz Narrative (with track changes)		
D0019 11	04/09/03	11:02 PM	Draft Wolkowitz Narrative (with track changes)		
D0019 12	04/09/03	11:03 PM	Draft Wolkowitz Narrative (with track changes)		
D0019 13	04/10/03	7:51 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: GSK's Supplemental Response to Question No. Attaching draft GSK supplemental response to Question 14	MAY 6 2011	MAY 6 2011
D0019 14	04/11/03	3:18 PM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: Wolkowitz - Revised Narrative, Attaching blackline draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 15	04/14/03	4:26 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL, LEGAL, COMMUNICATION, Attaching Draft Wolkowitz Narrative (with track changes)	MAY 6 2011	MAY 6 2011
D0019 16	04/14/03	4:51 PM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, N. Reeves, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL, LEGAL, COMMUNICATION, Attaching draft Wolkowitz Narrative (with track changes)	MAY 6 2011	MAY 6 2011
D0019 17	04/14/03	5:00 PM	Draft Wolkowitz Narrative		
D0019 18	04/14/03	5:01 PM	Draft Wolkowitz Narratives (with track changes and handwritten notes)		
D0019 19	04/14/03	5:02 PM	Draft Wolkowitz Narrative (with track changes)		
D0019 20	04/15/03	12:00 PM	Fax from N. Reeves to L. Stevens and S. Shade Re: GlaxoSmithKline Response to FDA Inquiry, Attaching draft Wolkowitz Narrative, list of Pride Events, 2001 & 2001 Speaker Events & fax transmission cover sheet		
D0019 21	04/15/03	12:01 PM	Letter from M. Brown to O. Wolkowitz Re: GlaxoSmithKline Response to FDA Inquiry, Attaching draft Wolkowitz Narrative, list of Pride Events, 2001 & 2001 Speaker Events & fax transmission cover sheet	MAY 6 2011	MAY 6 2011
D0019 22	04/17/03	5:39 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, ccd to M. Jensen, N. Reeves re: FW: CONFIDENTIAL: GSK response to FDA Inquiry (with handwritten notes)		
D0019 23	04/17/03	5:39 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, ccd to M. Jensen, N. Reeves re: FW: CONFIDENTIAL: GSK response to FDA Inquiry		
D0019 24	04/18/03	12:00 PM	Blackline of draft Wolkowitz Narrative (with handwritten notes)		
D0019 25	04/18/03	12:01 PM	Blackline of draft Wolkowitz Narrative		
D0019 26	04/19/03	12:02 PM	Draft Wolkowitz Narrative (with track changes)		
D0019 27	04/22/03	10:46 AM	Email from L. Stevens to M. Brown, D. Snyder, S. Shade, ccd to M. Jensen, N. Reeves re: RE: CONFIDENTIAL: GSK response to FDA Inquiry, Attaching Serotonin Special Issue Board Executive Summary		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0019 28	04/22/03	11:07 AM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder re: FW: Revised Wolkowitz Narrative; Attaching blackline of draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 29	04/22/03	11:07 AM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens re: FW: Revised Wolkowitz Narrative; Attaching GSK's draft response to multiple requests concerning Dr. Wolkowitz dated 04/21/03 (with blackline)		
D0019 30	04/22/03	11:48 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Dr. Attaching blackline of draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 31	04/22/03	11:49 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Dr. Attaching draft of Wolkowitz Narrative (with handwritten notes)		
D0019 32	04/22/03	10:19 PM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: Wolkowitz Revised; Attaching GSK's draft responses to requests concerning Dr. Wolkowitz dated 04/22/03 (with blackline)	MAY 6 2011	MAY 6 2011
D0019 33	04/22/03	10:39 PM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: WBSR: revised Wolkowitz narrative attached for your review; Attaching blackline of draft Wolkowitz Narrative		
D0019 34	04/23/03	9:58 AM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: RE: WBSR: revised Wolkowitz narrative attached for your review		
D0019 35	04/23/03	11:46 AM	Email from S. Shade to D. Snyder, M. Brown, M. Jensen, N. Reeves, ccd to L. Stevens re: Revised Wolkowitz letter; Attaching blackline of draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 36	04/23/03	12:00 PM	Email from M. Brown to S. Shade re: RE: Revised Wolkowitz letter		
D0019 37	04/24/03	5:03 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, M. Jensen, N. Reeves re: Urgent - Wolkowitz - See My Proposed Responses - Please comment		
D0019 38	04/24/03	5:47 PM	Email from M. Brown to M. Jensen, N. Reeves, S. Shade, D. Snyder, L. Stevens, re: RE: Urgent - Wolkowitz - See My Proposed Responses - Please comment		
D0019 39	04/25/03	12:50 PM	Email from M. Brown to S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: Wolkowitz Final Draft For Your Review; Attaching blackline of draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 40	04/25/03	1:02 PM	Email from L. Stevens to J. Lemieux, S. Shade re: Dr. Attaching blackline of draft Wolkowitz Narrative		
D0019 41	04/25/03	1:08 PM	Email from L. Stevens to M. Brown, D. Snyder, S. Shade, ccd to M. Jensen, N. Reeves re: RE: Wolkowitz Final Draft For Your Review		
D0019 42	04/25/03	1:30 PM	Email from L. Stevens to S. Shade re: RE: Dr		
D0019 43	04/25/03	2:33 PM	Email from L. Stevens to J. Lemieux, S. Shade re: Dr. Attaching blackline of draft Wolkowitz Narrative	MAY 6 2011	MAY 6 2011
D0019 44	04/28/03	8:01 AM	Email from L. Stevens to S. Shade re: RE: Letter to FDA - Privileged and Confidential	MAY 6 2011	MAY 6 2011
D0019 45	04/28/03	8:08 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: wolkowitz RespondInfo.xls; Attaching spreadsheet		
D0019 46	04/28/03	8:10 AM	Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI) Sustained-Release Tablets MACMIS #11170		
D0020			Summary Chart of 5/21/2003 Draft Letter		
D0020 1	04/09/03	12:07 PM	Email from M. Brown to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Jensen, N. Reeves re: Supplemental Response to No. 14; Attaching GSK's draft Supplemental Response to Question 14	MAY 6 2011	MAY 6 2011
D0020 2	04/09/03	12:30 PM	GSK's draft Supplemental Response to Question 14 with L. Stevens' comments (blackline with handwritten notes)		
D0020 3	04/09/03	12:35 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: GSK's Supplemental Response to Question No. Attaching draft GSK's Supplemental Response to Question 14 (blackline)		
D0020 4	04/09/03	1:00 PM	GSK's draft Supplemental Response to Question 14 (with comment)		

Page 16

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0020	29	05/14/03	5:27 PM Email from D. Snyder to M. Brown, ccd to D. Snyder, M. Jensen, J. Hetzel, J. Lemieux, S. Shade, N. Reeves re: Revised Response. Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets	MAY 6 2011	MAY 6 2011
D0020	30	05/15/03	9:34 AM Email from N. Reeves to L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel, ccd to M. Brown, M. Jensen re: GSK, WBSR: final version of response letter to FDA attached. Attaching clean, final copy of response letter to FDA	MAY 6 2011	MAY 6 2011
D0020	31	05/19/03	8:43 AM Email from L. Stevens to J. Lemieux, S. Shade re: FW: Draft Final Submission to FDA re: WBSR. Attaching draft final submission to FDA re: Wellbutrin investigation	MAY 5 2011	MAY 5 2011
D0020	32	05/22/03	Letter from J. Lemieux to M. Jensen. Attaching May 21, 2003 GSK response letter to FDA		
D0021			Summary Chart of 11/06/2003 Draft Letter		
D0021	1	10/25/03	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170		
D0021	2	10/26/03	8:34 PM Draft Letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170		
D0021	3	10/26/03	8:34 PM Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)		
D0021	4	10/29/03	7:59 AM Email from L. Stevens to S. Shade, T. Thelen, ccd to N. Reeves, M. Brown re: RE: Draft Letter to FDA re: Davico	MAY 6 2011	MAY 6 2011
D0021	5	10/30/03	8:05 AM Email from L. Stevens to D. Snyder re: Response to Requests No. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with comments)	MAY 6 2011	MAY 6 2011
D0021	6	10/30/03	8:28 PM Email from S. Shade to M. Brown, N. Reeves, ccd to L. Stevens, J. Lemieux, T. Thelen re: Draft Letter. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	MAY 6 2011	MAY 6 2011
D0021	7	10/30/03	8:28 PM Email from S. Shade to M. Brown, N. Reeves, ccd to L. Stevens, J. Lemieux, T. Thelen re: Draft Letter. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	MAY 6 2011	MAY 6 2011
D0021	8	10/31/03	9:55 AM Email from S. Shade to M. Brown, ccd to L. Stevens, J. Lemieux, T. Thelen, N. Reeves re: RE: Draft Letter		
D0021	9	10/31/03	10:22 AM October 31, 2002 Fax from D. Snyder to L. Stevens. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	MAY 6 2011	MAY 6 2011
D0021	10	10/31/03	10:25 AM Fax from D. Snyder to L. Stevens re: [no subject]. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 dated 10/26/03 (with handwriting)		
D0021	11	10/31/03	3:58 PM Email from C. Stellings to S. Shade, B. Shannon, L. Stevens re: RE: Draft Letter. Attaching draft letter to R. Williams with C. Stellings' comments	MAY 6 2011	MAY 6 2011
D0021	12	11/03/03	6:51 AM Email from B. Shannon to S. Shade, L. Stevens re: FW: Draft Letter		
D0021	13	11/03/03	3:14 PM Email from M. Brown to L. Stevens, S. Shade, D. Snyder re: Revised Letter. Attaching blackline draft letter to R. Williams with M. Brown's comments	MAY 6 2011	MAY 6 2011
D0021	14	11/04/03	8:00 AM Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline with handwritten notes)		
D0021	15	11/04/03	8:11 AM Email from L. Stevens to S. Shade re: Response to Requests No. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline with handwritten notes)		
D0021	16	11/04/03	4:51 PM Email from S. Shade to L. Stevens re: RE: Response to Requests No. Attaching revised draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)		
D0021	17	11/04/03	5:42 PM Email from S. Shade to D. Snyder, ccd to L. Stevens re: draft letter. Attaching revised draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)	MAY 6 2011	MAY 6 2011
D0021	18	11/05/03	12:47 PM Email from M. Brown to L. Stevens, S. Shade, D. Snyder re: Comments/Edits to Letter. Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)	MAY 6 2011	MAY 6 2011
D0021	19	11/05/03	1:23 PM Email from S. Shade to L. Stevens re: RE: Comments/Edits to Letter		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
DD0021	20	11/05/03	5:31 PM	Email from S. Shade to M. Brown re: RE: Comments/Edits to Letter	
DD0021	21	11/05/03	11:26 PM	Email from L. Stevens to S. Shade re: Cover Letter Via Facsimile Transmission (301) 594-6771; Attaching draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)	
DD0021	22	11/06/03	12:00 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170	
DD0021	23	11/06/03	12:01 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	
DD0021	24	11/06/03	12:02 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	
DD0021	25	11/06/03	12:03 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	
DD0021	26	11/06/03	12:04 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with handwritten notes)	
DD0021	27	11/06/03	12:05 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (blackline)	
DD0021	28	11/06/03	12:06 PM	Draft letter from L. Stevens to R. Williams re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with comment)	
DD0021	29	11/19/03		Letter from L. Stevens to M. Jensen, Attaching November 6, 2003 GSK submission to FDA	
DD0022		03/30/01		Fax from D. Childs to K. Fujioka re: Contract for teleconferences; Attaching Consulting and Services Agreement between SmithKline Beecham Corporation and K. Fujioka	
DD0023		04/03/01	8:50 PM	Email from I. Acosta to I. Acosta, A. Davico, E. Guthrie, L. Kearsey, D. Keck, J. Mirich, E. Morales, D. Smith, C. Warren, S. Wotke, B. Zieber re: FW: Dash & Whatever	
DD0024		07/06/01		Consulting and Services Agreement between SmithKline Beecham Corporation and K. Fujioka	
DD0025		09/05/01	1:00 PM	Email from M. Rodriguez to D. Henning, R. Lozano, G. Rose, J. Rosner, K. Steinberg re: FW: DD/MAC Surveillance Activities	
DD0026		10/01/01	4:00 PM	Email from D. Stout, J. Daly, P. Hare, S. Hull, J. Jabara, K. Lokay, D. Pernock, S. Stefano to GSK US Pharma Personnel re: Questions and Answers Relating to GSK Policies on Commercial Practices; Attaching GSK Policies	
DD0027		10/30/01		Advisory Board Consultant Agreement between GlaxoSmithKline and K. Fujioka	
DD0028		04/05/02	12:08 PM	Email from J. McNeill to R. Moscano, A. Long, H. Mintz, T. Nye, J. Palazzo, J. Parks, M. Register, L. Shephard and T. Switzer, ccd to T. Nichols re: FW: FYI - Wellbutrin SR CME Express ACTION REQUIRED; Attaching Fax and CME ExpressProcess	
DD0029		04/16/02	1:13 PM	Email from US Pharma Internal Communications ccd to various re: Must Read-Revised Speaker Event Policy and Informational Memos; Attaching memorandum from D. Stout, K. Lokay, J. Jabara, P. Hare, S. Hull, D. Pernock, S. Stefano, D. Tulp, D. White	
DD0030		05/14/02	12:56 AM	Draft Email from L. Stevens to M. Schwartz, ccd to D. Huber and J. Lamb re: RE: Another Teleconference Question	
DD0031		06/05/02	9:30 AM	Draft E-mail from A. Rosen to C. Gardener and S. Hull, ccd to J. Millar, M. Werner and S. Shade re: RE: Teaching Guidelines	
DD0032		10/07/02	8:17 AM	Email from J. Millar to S. Shade, ccd to D. Guterman re: RE: PRIVILEGED AND CONFIDENTIAL - Dr. Pradko; Attaching Regulatory Requirements for Speakers	
DD0033		10/10/02	7:11 AM	Email from J. Murray to R. Dubose, ccd to A. Rosen, K. Collins, M. Martinson, R. Sluder, S. Shade re: RE: Correspondence DD/MAC - Wellbutrin SR	
DD0034		10/10/02	1:07 PM	Email from J. Lemieux to L. Stevens, S. Shade, J. Hetzel re: FDA Letter - WBSR; Attaching ACTION PLAN - FDA letter on WBSR	
DD0035		10/10/02	1:10 PM	Email from R. Hatchut to T. Thelen, ccd to R. Richardson re: RE: FDA Investigation Into Activities Relating to Wellbutrin	

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0036	10/10/02	3:01 PM	Email from J. Millar to S. Shade, L. Stevens re: FW: More Wolkowitz...; Attaching tables showing Dr. Wolkowitz's 2000 and 2001 PRIDE talks		
D0037	10/13/02	11:02 AM	Email from J. Millar to S. Shade, L. Stevens, D. Guterman re: FW: Payment Info		
D0038	10/15/02	3:16 PM	Email from T. Thelen to D. Snyder, J. Murray, L. Stevens re: RE: FDA LETTER		
D0039	10/17/02	12:23 PM	Email from S. Shade to V. Stowe, A. Teagle re: PRIVILEGED AND CONFIDENTIAL		
D0040	10/18/02	10:22 AM	E-mail from T. Thelen to L. Stevens, J. Schell and M. Werner, ccd to S. Shade re: RE: [no subject]		
D0041	10/18/02	11:09 AM	E-mail from L. Stevens to M. Werner and J. Schell, ccd to T. Thelen and S. Shade re: RE: [no subject]		
D0042	10/21/02	9:39 AM	Email from T. Thelen to D. Snyder, J. Murray, L. Stevens, ccd to S. Shade re: RE: WBSR FDA 10.16.02.doc		
D0043	10/30/02	4:45 PM	Email from S. Shade to J. Lemieux re: FW: Work Product, Attaching list of all Dr. Wolkowitz's speaking engagements as of 10/18/02		
D0044	10/30/02	6:58 PM	Email from S. Shade to J. Lemieux re: FW: Payment Info		
D0045	10/30/02	7:05 PM	Email from S. Shade to J. Lemieux re: Owen Wolkowitz Events-WORK PRODUCT, Attaching reports for Owen Wolkowitz Event Names for SEAS and PET		
D0046	10/30/02	7:07 PM	Email from S. Shade to J. Lemieux re: FW: PRIVILEGED AND CONFIDENTIAL; Attaching Promotional Speaker Events, Advisory Board Meetings and Speaker Training Meetings activity since 1998 for D. Ryan, O. Wolkowitz, J. Anderson		
D0047	10/31/02	4:04 PM	Email from S. Shade to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Brown, T. Thelen, ccd to L. Stevens re: Project Plan - PRIVILEGED AND CONFIDENTIAL; Attaching Draft Project Plan 10/31/02		
D0048	10/31/02	5:04 PM	Email from S. Shade to T. Thelen, D. Hanley, D. Snyder, J. Lemieux, J. Hetzel, M. Brown, M. Jensen re: Project Plan - PRIVILEGED AND CONFIDENTIAL; Attaching Draft Project Plan dated 10/31/02		
D0049	10/31/02	6:56 PM	Email from S. Shade to V. Stowe, ccd to J. Lemieux re: PRIVILEGED AND CONFIDENTIAL/ATTORNEY WORK PRODUCT		
D0050	10/31/02		Invoices from 10/31/2002-11/30/2003 from King & Spalding to GlaxoSmithKline, PLC Re: Wellbutrin Investigation		
D0051	11/01/02	5:48 PM	Email from L. Stevens to P. Gaegler, A. Rosen, S. Shade, M. Nowell, re: FW: Advisory Boards - Wellbutrin SR		
D0052	11/04/02	9:56 AM	Email from P. Gaegler to L. Stevens, S. Shade re: FW: Advisory Boards -- Wellbutrin SR		
D0053	11/04/02		R. Moscatto To Do list		
D0054	11/04/02		V. Stowe PRIORITY To-Do List for Professional Programs		
D0055	11/05/02	1:39 PM	Email from M. Brown to L. Stevens, ccd to D. Snyder, S. Shade, T. Thelen, M. Jensen re: RE: Information Request Letters - Action Needed		
D0056	11/05/02	3:10 PM	Email from L. Stevens to M. Brown, ccd to D. Snyder, S. Shade, T. Thelen, M. Jensen re: RE: Information Request Letters - Action Needed		
D0057	11/05/02	4:57 PM	Email from L. Stevens to M. Jensen, ccd to T. Thelen, D. Snyder, S. Shade, J. Lemieux, M. Brown re: Re: Q & A's, Interview Schedule		
D0058	11/05/02		Letter from D. Hanley to M. Jensen re: Wellbutrin SR FDA Matter (with handwritten notes); 10/29/02 Letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170; 10/29/02 fax cover		
D0059	11/06/02	11:14 AM	Email from J. Modell to L. Stevens, ccd to D. Cline, J. Murray, J. Lemieux, M. Martinson, M. Brown, M. Jensen, S. Shade, T. Thelen re: Query from FDA regarding CD-ROM slide set	APR 29 2011	APR 29 2011

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0060	11/06/02	4:18 PM	Email from L. Stevens to D. Stout, S. Hull, D. Wheadon, A. Rajaraman, D. Guterman, L. Gonzalez, ccd to M. Werner re: FDA Inquiry. Attaching 10/29/02 letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (duproption HCD) Sustained-		
D0061	11/06/02	4:31 PM	Email from L. Stevens to M. Jensen, D. Snyder, S. Shade, T. Thelen, J. Lemieux, M. Brown re: RE: Lesley Frank		
D0062	11/06/02	4:51 PM	Email from D. Snyder to L. Stevens, ccd to S. Shade, T. Thelen, M. Jensen, M. Brown, J. Lemieux re: Re: Lesley Frank, Attaching S. Hull's revisions to letters to doctors and sales reps.		
D0063	11/11/02	10:23 AM	Email from A. Rosen to S. Shade, L. Stevens, J. Lemieux re: FW: Follow-up on Psychiatry Local Ad Board Meetings for 02. [sic]. Attaching D1 Region Psychiatry Local Advisory Board Meeting, June 7-9, 2002 at the Marriott Hotel, Newport, RI		
D0064	11/11/02	11:47 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]. Attaching draft GSK communications to sales representatives and doctors requesting presentation materials, and Draft Questions & Answers		
D0065	11/11/02	11:55 AM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, T. Thelen, ccd to M. Brown re: Draft Q&As, Attaching Draft Questions & Answers		
D0066	11/11/02	2:30 PM	Email from R. Moscatto to J. Lemieux, ccd to D. Slatery re: RE: FDA Inquiry - Privileged and Confidential	APR 29 2011	APR 29 2011
D0067	11/11/02	5:56 PM	Email from L. Stevens to M. Jensen, M. Brown re: FW: RMS Speaker Training Update Slides (without attachments)	APR 29 2011	APR 29 2011
D0068	11/11/02	7:37 PM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, L. Stevens, T. Thelen re: November 11, 2002; Attaching 11/21/02 draft letter to D. Ryan re: FDA Inquiry Of [sic] GlaxoSmithKline		
D0069	11/12/02	7:07 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen [no subject]. Attaching GSK Letters to Physicians and Sales Representatives Requesting Promotional Information (with blackline)		
D0070	11/15/02	10:00 AM	Email from M. Jensen to L. Stevens, T. Thelen, D. Snyder, S. Shade, ccd to M. Brown re: Interview Outline, Attaching Topic Outline for GSK Wellbutrin SR Interviews November 11-12, 2002		
D0071	11/15/02	10:42 AM	Email from S. Shade to M. Martinson re: RE: Response to Q. 15		
D0072	11/15/02	1:39 PM	Email from L. Stevens to M. Martinson, ccd to J. Murray, J. Lemieux, S. Shade re: RE: Submission of documents scheduled for today		
D0073	11/15/02	2:11 PM	Email from A. Rosen to S. Shade, J. Lemieux, L. Stevens re: FW: Follow-up on Psychiatry Local Ad Board Meetings for 02. [sic]		
D0074	11/15/02	7:06 PM	Email from L. Stevens to S. Hull, L. Gonzalez, D. Guterman, J. Miller, M. Burke, M. Martinson, J. Murray, V. Stowe, B. Judd, T. Cardiff, T. Poe, E. Collins, D. Wheadon, ccd to S. Shade, J. Lemieux, J. Hetzel, M. Werner re: Communications regarding programs; Attaching 11/18/02 memorandum from L. Stevens to GSK Sales Representatives with Promotional Responsibility for		
D0075	11/15/02	7:08 PM	Email from L. Stevens to M. Burke, ccd to J. Lemieux, S. Shade re: FW: Communications regarding Wellbutrin speaker programs; Attaching 11/18/02 memorandum from L. Stevens to GSK Sales Representatives with Promotional Responsibility for		
D0076	11/17/02	11:57 AM	Email from L. Stevens to M. Jensen, M. Brown, ccd to D. Snyder, S. Shade, T. Thelen re: RE: Interview Outline, Attaching Topic Outline for GSK Wellbutrin SR Interviews November 11-12, 2002 (with track changes)		
D0077	11/17/02	5:26 PM	Email from M. Jensen to L. Stevens, ccd to M. Brown, S. Shade, D. Snyder, T. Thelen re: Interview Outline, Attaching Topic Outline for GSK Wellbutrin SR Interviews November 11-12, 2002		
D0078	11/20/02	1:42 PM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade, J. Lemieux re: FW: Scott Levin data on WBSR uses, Attaching Wellbutrin SR Uses by Indication	APR 29 2011	APR 29 2011
D0079	11/20/02	7:37 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: November 11, 2002; Attaching 11/21/02 letter from L. Stevens to D. Ryan		
D0080	11/21/02	8:43 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: November 11, 2002; Attaching letter from L. Stevens to D. Ryan re: FDA Inquiry Of [sic] GlaxoSmithKline dated 11/21/02 (without		
D0081	11/21/02	10:24 AM	Fax cover sheet from L. Stevens to D. Ryan		
D0082	11/21/02	11:40 AM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade re: Dr. Ryan Interview today		
D0083	11/21/02	6:03 PM	Email from L. Stevens to M. Jensen, M. Brown re: FW: Pradko 11-15-02 Notes, Attaching "Neuroreceptor Basis of Initial Antidepressant Choice" dated 11/15/02		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0084	11/22/02	12:55 PM	Email from L. Stevens to J. Lemieux re: FW: [no subject]. Attaching screenshot of all versions of WLJCTRS72		
D0085	11/23/02	8:11 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: FW: Washington Post inquiry		
D0086	11/24/02		Fax from J. Pradko to J. Miller, Attaching J. Pradko's presentation slides, "Neuroreceptor Basis of Initial Antidepressant Choice" Copyright 1999, 2002 (with handwritten notes)		
D0087	11/24/02		Fax from J. Pradko to J. Miller, Attaching J. Pradko's presentation slides, "Neuroreceptor Basis of Initial Antidepressant Choice" Copyright 1999, 2002		
D0088	11/25/02	6:30 AM	Email from L. Stevens to J. Murray, M. Martinson, ccd to S. Shade, J. Lemieux re: WBSR Investigation-Brief update		
D0089	11/25/02	8:14 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: Update, Table of documents collected	APR 29 2011	APR 29 2011
D0090	11/26/02	10:34 AM	Email from V. Stowe to L. Esposito, ccd to T. Star, J. Lemieux re: FW: WEL Spkr Info - Privileged and Confidential		
D0091	11/26/02	12:47 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: Today's Meeting: Attaching history of slides dated 11/26. Summary of Documents and Information Requested from Interviews (11/18/02)		
D0092	11/26/02	6:06 PM	Email from L. Esposito to M. Giordano, ccd to C. Curcua re: WEL Speaker Information		
D0093	11/27/02		Signed Letter from J. Lemieux to M. Jensen		
D0094	12/02/02	12:20 PM	Email from L. Stevens to D. Snyder, M. Jensen, M. Brown, S. Shade, T. Thelen re: DRAFT RESPONSE TO OWEN WOJ.KOWIYZ [sic]		
D0095	12/02/02	1:42 PM	Email from L. Stevens to A. Rajaraman re: Request for Investigation	MAY 5 2011	MAY 5 2011
D0096	12/03/02	8:26 AM	Email from L. Stevens to M. Burke, ccd to J. Lemieux, S. Hull, L. Gonzalez, S. Shade re: Letter to doctors - Heads up		
D0097	12/03/02	10:12 AM	Email from J. Hamaker to J. Lemieux re: RE: PRIDE Speaker Training 1-01 - PRIVILEGED AND CONFIDENTIAL: Attaching list of doctors who attended the 1-01 speaker training		
D0098	12/03/02		Memorandum from L. Stevens to GSK Sales Representatives with Promotional Responsibility for Wellbutrin SR re: Request to Physicians for Presentation Materials Relating to Wellbutrin SR (bupropion HCl) Sustained-Release Tablets		
D0099	12/03/02		GSK WSR Investigation, Next Steps		
D0100	12/04/02	8:43 AM	Email from L. Stevens to L. Gonzalez re: Dr. Pradko		
D0101	12/08/02	9:56 PM	Email from L. Stevens to O. Wolkowitz, ccd to M. Jackson re: FW: presentations		
D0102	12/09/02	9:54 AM	Email from S. Shade to M. Brown, M. Jensen re: Dr. Pradko, Attaching letter from J. Millar to J. Pradko dated 12/09/02		
D0103	12/09/02	6:51 PM	Email from S. Shade to J. Millar, ccd to A. Zgonice re: FW: Letter to Pradko, Attaching draft 12/10/02 letter from J. Millar to J. Pradko re: Wellbutrin SR presentations' compliance with FDA requirements & GSK contractual requirements		
D0104	12/10/02		Letter from J. Millar to J. Pradko, MD re: compliance of presentations on behalf of GSK relating to Wellbutrin SR with FDA requirements		
D0105	12/11/02	1:58 PM	E-mail from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder and T. Thelen re: FW: Dear Doctor Letter: Request to Physicians for Presentation Materials Relating to Wellbutrin SR (bupropion HCl) Sustained-		
D0106	12/12/02	1:11 PM	Email from J. Lemieux to L. Stevens re: FW: Additional Wellbutrin Information, Attaching three Wellbutrin reports		
D0107	12/12/02		Letter from L. Stevens re: Wellbutrin SR (bupropion HCl) Sustained-Release Tablets Request for Presentation Materials Used at GSK-Sponsored Programs		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0108	12/12/02		Letter from L. Stevens re: Wellbutrin SR (bupropion HCI) Sustained-Release Tablets Request for Presentation Materials Used at GSK-Sponsored Programs (with handwritten note of 12/20/02)	REV 3 2011 REV 3 2011	REV 3 2011
D0109	12/12/02		Letter from L. Stevens to doctor re: Wellbutrin SR (bupropion HCI) Sustained-Release Tablets Request for Presentation Materials Used at GSK-Sponsored Programs		
D0110	12/13/02	2:58 PM	Email from L. Stevens to M. Jensen, M. Brown re: MEMO TO THE FILE. Attaching Memo to the file from A. Rosen dated 12/13/02		
D0111	12/15/02	10:31 AM	Email from L. Stevens to M. Brown, cc'd to M. Werner, D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, S. Shade, D. Snyder, T. Thelen re: Confidential Legal Communication		
D0112	12/16/02	7:02 AM	Email from L. Stevens to M. Jensen, cc'd to M. Brown, D. Snyder, T. Thelen re: RE: Teleconference with Dr. Clayton		
D0113	12/17/02	2:00 PM	Email from K. Kilburn to L. Stevens, S. Shade, cc'd to J. Lemieux re: Add-on List to Top 500. 12/18/02 8:23 am Email from L. Stevens to J. Lemieux re: FW: Add-on List to Top 500 and 12/11/02 1:41 pm Email from L. Stevens to J. Lemieux re: FW: Dear	REV 3 2011	REV 3 2011
D0114	12/17/02	6:46 PM	Email from L. Stevens to M. Jensen, M. Brown, cc'd to S. Shade, J. Lemieux re: Spread sheets. Attaching final spreadsheets for speaker event database		
D0115	12/19/02	6:37 AM	Email from L. Stevens to A. Rosen re: FW: Description of presentation by Dr. James Pradko		
D0116	12/19/02	6:45 AM	Email from L. Stevens to L. Stevens, D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: RE: DRAFT 11/07/02 PRIVILEGED/CONFIDENTIAL [sic]		
D0117	12/20/02		Letter from A. Jorgensen to L. Stevens re: Your letter of request - December 12, 2002		
D0118	12/23/02		Letter from L. Clinton to L. Stevens re: presentation materials		
D0119	12/27/02		Letter from D. Bolick to L. Stevens re: request for materials		
D0120	01/07/03	12:48 PM	Email from J. Lemieux to J. Riddle-Wilson re: FW: Presentation Materials for Wellbutrin SR		
D0121	01/07/03	6:25 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: Confirmation of next meeting		
D0122	01/09/03		Letter from J. Lemieux to M. Jensen [no subject]. Attaching PRIDE 2002 Event Report from SCSA		
D0123	01/10/03		Letter from J. Lemieux to C. Daum re: response to request for materials		
D0124	01/11/03	11:10 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen [no subject]. Attaching document collection excel sheet dated 11/26/02. Response from Doctors dated 01/14/03		
D0125	01/13/03		Letter from J. Lemieux to M. Jensen [no subject]. Attaching list of documents produced to FDA, PRIDE Event report - 2001		
D0126	01/14/03		Letter from J. Lemieux to D. Bolick re: response to request for materials		
D0127	01/16/03	3:42 PM	Email from S. O'Quinn to J. Lemieux, cc'd to J. Millar, J. Hamaker re: RE: Privileged and Confidential - Wellbutrin Speaker Training Attendees		
D0128	01/17/03	6:35 PM	Email from L. Stevens to A. Rosen, P. Gaugler, S. Lyford, T. Crandall to S. Shade, J. Lemieux re: PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION. Attaching 2/12/02 draft letter from L. Stevens to doctors re:		
D0129	01/21/03	7:32 AM	Email from L. Stevens to J. Lemieux, S. Shade, cc'd to M. Brown, M. Jensen, N. Reeves, re: RE: Trained Speaker [sic] who have spoken		
D0130	01/24/03	4:39 PM	Email from M. Jensen to L. Stevens, T. Thelen, D. Snyder, S. Shade, cc'd to M. Brown, N. Reeves re: Letters relating to doctor presentations. Attaching drafts of GSK letters to physicians confirming receipt of their presentation materials and reminding		
D0131	01/25/03	1:00 PM	Email from L. Stevens to M. Brown, M. Jensen, N. Reeves, cc'd to S. Shade, J. Lemieux, D. Snyder re: PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION SUBJECT TO ATTORNEY WORK PRODUCT DOCTRINE.		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0132	01/28/03	12:10 PM	Fax from C. Gessner to K. Fujioka re: Confirmation Letter; Attaching Letter Amendment to the GSK Speakers Events or Member Profile Form Agreement re: Speaker Event Confirmation; Amendment to GSK Agreement with GSK Speaker Events;		
D0133	01/29/03	1:38 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: [no subject]; Attaching PRIDE 2001 & 2002 databases		
D0134	01/29/03	3:57 PM	Email from M. Brown to J. Lemieux, L. Stevens, M. Jensen, N. Reeves, S. Shade re: RE: [no subject] (with handwritten notes)		
D0135	01/30/03	8:30 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: [no subject]; Attaching GlaxoSmithKline Speaker Event Database - Wellbutrin SR - 2001-2002		
D0136	01/30/03	9:46 AM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, D. Snyder, ccd to L. Stevens, J. Lemieux re: T-con Memo; Attaching 1/30/03 Memo from L. Stevens to M. Brown, M. Jensen, N. Reeves re: Teleconference with FDA on January 21, 2003		
D0137	02/03/03	3:13 PM	Email from J. Lemieux to N. Reeves, ccd to M. Brown, M. Jensen, L. Stevens, S. Shade re: RE: Question re: physician speaker numbers		
D0138	02/04/03	2:23 PM	Email from J. Lemieux to M. Brown, N. Reeves, ccd to M. Jensen, L. Stevens, S. Shade re: RE: Question re: physician speaker numbers		
D0139	02/04/03	3:13 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves re: Updated categorization of doctors' presentations		
D0140	02/04/03		List of documents indicating whether to produce to FDA and whether provided to King & Spalding		
D0141	02/04/03		Letter from J. Lemieux to M. Jensen (no subject and without enclosures)		
D0142	02/05/03	3:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, J. Lemieux, J. Hetzel, D. Snyder, ccd to L. Stevens re: Teleconference Agenda (with handwritten notes)		
D0143	02/07/03		Letter from L. Stevens to J. Pradko re: January 24th meeting		
D0144	02/12/03	3:31 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Abridged Database; Attaching database of speaker programs with off-label titles		
D0145	02/12/03		Letter from M. Brown to J. Anderson re: GlaxoSmithKline Response to FDA Inquiry		
D0146	02/12/03		Letter from M. Brown to D. Ryan re: GlaxoSmithKline Response to FDA Inquiry, ccd to L. Stevens and bcc'd to D. Snyder, S. Shade, M. Jensen and N. Reeves		
D0147	02/13/03	10:30 PM	Email from S. Shade to M. Jensen, N. Reeves, ccd to M. Brown, J. Lemieux re: Speaker Presentations; Attaching Review of Doctor Responses dated 02/13/03		
D0148	02/13/03		Review of Doctor Responses; Category I Presentation(s) On-Label		
D0149	02/13/03		Review of Doctor Responses; Category IV - Doc Responded But Presentation(s) Not Sent (with handwritten notes)		
D0150	02/15/03	10:09 AM	Email from L. Stevens to J. Lemieux, S. Shade re: FW: Communication from BUH re: Speaker Events Policy; Attaching letter from S. Hull		
D0151	02/15/03	12:17 PM	Email from L. Stevens to L. Gonzalez, ccd to S. Shade re: Coaching and Counseling Sessions; Attaching list of speaker programs that appear inconsistent with policy requiring "on-label" topics and 02/15/03 draft memorandum from L. Gonzalez to Draft 03/07/03 memorandum from L. Stevens to A. Kirsch re: Coaching and Counseling Speaking Points for RVPs		
D0152	02/15/03				
D0153	02/18/03	5:01 PM	Email from L. Stevens to J. LeCoulhard, S. Hull, K. Lokay, D. Pernock, P. Hare, S. Stefano, D. Tulp, ccd to M. Werner, J. Schell, C. Viehbocker, D. Wheldon, D. Sullivan, B. Lortie, L. Campbell, M. Kohler, S. Shade, D. Pennod, D. Snyder, A. Rosen,	MAY 3 2011	MAY 3 2011
D0154	02/19/03	12:33 PM	Email from P. Thompson on behalf of L. Gonzalez to L. Stevens, ccd to S. Shade re: RE: Coaching and Counseling Sessions		
D0155	02/19/03	3:32 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves, ccd to L. Stevens, S. Shade, re: RE: Speaker Utilization		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0156	02/20/03	9:44 AM	Email from L. Stevens to L. Gonzalez, cc'd to S. Shade re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION; Attaching list of post-06/04/01 programs requiring coaching and counseling		
D0157	02/22/03	11:25 AM	Email from L. Stevens to O. Wolkowitz re: RE: Wellbutrin talks	MAY 3 2011	MAY 3 2011
D0158	02/23/03	11:27 PM	Email from L. Stevens to O. Wolkowitz re: RE: Wellbutrin talks (printed by M. Brown)	MAY 3 2011	MAY 3 2011
D0159	02/23/03	11:27 PM	Email from L. Stevens to O. Wolkowitz re: RE: Wellbutrin talks (printed by J. Lemieux)		
D0160	03/06/03	7:29 AM	Email from L. Stevens to J. Lemieux re: FW: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION		
D0161	03/06/03	7:36 AM	Email from L. Stevens to J. Lemieux re: FW: [no subject] (with handwritten notes); Attaching program information discussed with D. Diono		
D0162	03/06/03	7:36 AM	Email from L. Stevens to J. Lemieux re: FW: Coaching and Counseling Request; Attaching 03/05/03 memo from S. Sullivan to D. Tulp, cc'd to L. Stevens re: RVP Coaching and Counseling; Attaching spreadsheet of inappropriate speaker topics		
D0163	03/06/03	7:37 AM	Email from L. Stevens to J. Lemieux re: FW: IMMEDIATE ACTION REQUIRED; Attaching 02/15/03 draft memorandum from L. Gonzalez to CNS RVPs, cc'd to L. Stevens re: Coaching and Counseling Speaking Points for RVPs		
D0164	03/06/03	7:37 AM	Email from L. Stevens to J. Lemieux re: FW: Paul Field #3; Attaching program discussed with S. Wright		
D0165	03/06/03	7:37 AM	Email from L. Stevens to J. Lemieux re: FW: Paul Field #4; Attaching program information discussed with C. Sandwisch		
D0166	03/06/03	6:02 PM	Email from L. Stevens to J. Lemieux re: FW: IMMEDIATE ACTION REQUIRED--PRIVILEGED [sic]/CONFIDENTIAL; Attaching 2/17/03 memo from L. Gonzalez to CNS RVPs, cc'd to L. Stevens re: Coaching and Counseling Speaker Points for		
D0167	03/06/03	6:04 PM	Email from L. Stevens to M. Delea, cc'd to L. Gonzalez re: RE: IMMEDIATE ACTION REQUIRED-- PRIVILEGED/CONFIDENTIAL; Attaching spreadsheet of speaker topics		
D0168	03/06/03	6:06 PM	Email from L. Stevens to J. Lemieux re: FW: GSK Sponsored Speaker Programs		
D0169	03/07/03	7:24 AM	Email from L. Stevens to J. Lemieux re: FW: PRIVILEGED/CONFIDENTIAL; Attaching 2/26/03 letter to Chris re: Dr. Ulrich's program		
D0170	03/07/03	1:46 PM	Email from L. Stevens to J. Lemieux re: PRIVILEGED/CONFIDENTIAL [sic]; Attaching 03/07/03 memorandum from R. Rancourt to L. Gonzalez, cc'd to L. Stevens re: Coaching and Counseling		
D0171	03/07/03	2:07 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: SE Database Rev4 - 03 05 03.xls PRIVILEGED/CONFIDENTIAL; Attaching 2/21/03 memorandum from D. Tulp to NeuroHealth RVPs, cc'd to L.		
D0172	03/07/03	2:47 PM	Email from L. Stevens to A. Kirsch re: [no subject]; Attaching speaking points for coaching and counseling session, grid of event times, topics and responsible sales representatives, and a communication from Business Unit heads to be disseminated by D.		
D0173	03/07/03	3:57 PM	Email from L. Stevens to D. White re: FW: BUH Voicemail Communication Regarding Speaker presentations; Attaching draft communication to sales personnel		
D0174	03/07/03	5:29 PM	Email from L. Stevens to J. Lemieux re: FW: Privileged/Confidential - Re: Action Req'd - Coaching & Counseling		
D0175	03/07/03	5:36 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL SUBJECT TO ATTORNEY [sic] WORK PRODUCT; Attaching GlaxoSmithKline Speaker		
D0176	03/08/03	10:13 AM	Email from M. Brown to D. Hagan re: FW: Speaker Events Topics; Attaching 02/15/03 draft memorandum from L. Gonzalez to CNS RVPs, cc'd to L. Stevens re: Coaching and Counseling Speaking Points for RVPs		
D0177	03/12/03		Memo from J. Schmidt to L. Stevens re: Coaching and Counseling Documents; Attaching coaching and counseling documents from the CNS RVPs (with handwritten notes)		
D0178	03/14/03	12:20 PM	Email from M. Jensen to J. Lemieux re: RE: Conf. Call		
D0179	03/15/03	7:50 PM	Email from L. Stevens to J. Lemieux re: FW: IMMEDIATE ACTION REQUIRED--PRIVILEGED [sic]/CONFIDENTIAL (with handwritten notes)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
DO180	03/17/03	8:21 AM	Email from L. Stevens to A. Kirsch re: RE: [no subject]		
DO181	03/17/03	5:34 PM	Email from L. Stevens to J. Lemieux re: FW: FW: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION, Attaching spreadsheet regarding representative counseling		
DO182	03/17/03	11:17 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: [no subject]		
DO183	03/19/03	10:28 AM	Email from L. Stevens to J. Lemieux re: FW: Speaker Events Topics: Attaching 3/7/03 memo from J. Murray to C. Flannery, cc'd to L. Stevens re: Coaching and Counseling Speaking Points for RVPs; Attaching information about speaker event program		
DO184	03/19/03	11:27 AM	Email from L. Stevens to J. Lemieux re: FW: BUH Voicemail Communication Regarding Speaker presentations; Attaching letter reminder for all sales personnel		
DO185	03/20/03	4:58 PM	Email from L. Stevens to J. Lemieux re: RE: Coaching & Counseling stuff and Email from L. Stevens to A. Kirsch re: RE: [no subject]		
DO186	03/25/03	7:02 AM	Email from L. Stevens to A. Kirsch re: RE: [no subject]		
DO187	03/27/03	5:28 PM	Email from L. Stevens to N. Reeves, M. Jensen, M. Brown, cc'd to S. Shade, J. Lemieux re: FW: SIB Information; Attaching GlaxoSmithKline Serotonin Special Issue Board, January 11-14, 2001 Ritz-Carlton Kapalua, Maui, HI Attendee List		
DO188	03/28/03	7:49 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: FW: FW: SIB Information; Attaching Serotonin Special Issue Board agenda, executive summary		
DO189	04/10/03	10:16 AM	Email from J. Lemieux to L. Stevens, J. Hetzel, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION- Wolkowitz Presentation; Attaching Excel spreadsheet		
DO190	04/17/03	6:29 PM	Email from S. Shade to M. Brown, D. Snyder, L. Stevens re: RE: CONFIDENTIAL: GSK response to FDA Inquiry		
DO191	04/21/03	12:21 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, cc'd to M. Brown, N. Reeves re: Revised Wolkowitz Narrative; Attaching draft Wolkowitz Narrative (with track changes)		
DO192	04/23/03	6:52 PM	Fax from M. Brown to O. Wolkowitz re Revised Version of Narrative of GSK's response to multiple requests concerning Dr. Wolkowitz, including Request Numbers 2, 4, 5, 6, 7, 8, 9, 10, 13		
DO193	04/30/03		Summary chart of documents sent to King & Spalding		
DO194	05/01/03	4:45 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Arrange meeting		
DO195	05/05/03	12:24 PM	Email from L. Stevens to J. Lemieux re: FW: Speaker Events Topics Policy Discussion; Attaching 3/24/03 memo from C. Flannery to J. Murray, cc'd to L. Stevens		
DO196	05/08/03	1:07 PM	Email from L. Stevens to J. Lemieux re: FW: CNS Sales CPP Compliance Confirmations; Attaching Emails		
DO197	05/14/03	5:56 PM	Email from L. Stevens to M. Brown, D. Snyder, S. Shade, J. Lemieux, J. Hetzel, cc'd to M. Jensen, N. Reeves, re: RE: Revised Response		
DO198	05/22/03	9:52 AM	Email from M. Brown to J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder, L. Stevens re: RE: [no subject]	3 MAY 2011	3 MAY 2011
DO199	05/23/03	4:50 PM	Email from T. Mercer to C. Viehhaber, P. Hare, S. Hull, J. LeCoulthard, K. Lokay, A. McClafferty, D. Pernock, S. Stefano, D. Tulp, D. White, K. Ofce, W. Collier, S. Sons, J. Willett, J. Davis, W. Shulby, M. Werner, J. Schell, cc'd to C. Gardener, D.		
DO200	06/05/03	2:50 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: [no subject]	APR 28 2011	APR 28 2011
DO201	06/16/03	10:10 AM	Email from M. Jensen, L. Stevens, D. Snyder, S. Shade, J. Lemieux, J. Hetzel, cc'd to M. Brown, N. Reeves re: Draft Responses to Potential FDA Conf. Call Questions; Attaching 06/16/2003 memo from M. Brown to L. Stevens re: Talking Points for Follow-		
DO202	06/19/03	8:52 AM	Email from L. Stevens to C. Mangel, P. Gaegler, A. Rajagran, S. Shade, J. Schell, M. Werner re: FW: RMS training of speakers; Coordination with Professional Programs		
DO203	06/24/03	7:21 AM	Email from L. Stevens to M. Jensen, M. Brown, N. Reeves, cc'd to J. Lemieux, S. Shade, D. Snyder re: FW: Letter to Speakers for Wellbutrin SR (with handwritten note); Attaching 6/24/03 memorandum from S. Hull, D. Tulp to All CNS & Neurohealth		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
DO204	06/24/03	9:34 AM	Email from S. Shade to L. Stevens, J. Lemieux re: RE: Letter to Speakers for Wellbutrin SR		
DO205	06/26/03		Letter from L. Stevens to K. Fujioka re: Wellbutrin SR® (bupropion HCl) Sustained-Release Tablets - Response to GSK Request for Presentation Materials Used at GSK-Sponsored Programs		
DO206	07/11/03	2:31 PM	Email from D. Snyder to R. Miller, cc'd to L. Stevens, P. Gaegler, A. Rosen re: RE: Speaker Training FAQs and Evaluation; Attaching GSK Speaker Program Policy FAQs (Frequently Asked Questions)		
DO207	08/07/03		Letter from L. Stevens to M. Zeln, cc'd to C. Mercer, J. Muller, A. Talton, E. Collins, S. Shade, J. Lemieux, J. Wade re: response to request for materials; Attaching copy of envelope addressed from M. Zeln to L. Stevens		
DO208	08/15/03	9:30 AM	Email from J. Lemieux to L. Stevens, S. Shade re: RE: Phys who have not responded to 7-26 letter		
DO209	09/03/03	9:07 AM	Email from L. Stevens to S. Hull re: Follow up letter to speakers; Attaching draft follow up letter to speakers		
DO210	09/09/03	9:43 AM	Email from J. Lemieux to L. Stevens re: FW: Phys who have not responded to 7-26 letter (with handwritten notes)		
DO211	09/09/03	6:04 PM	Email chain from L. Stevens to J. Lemieux re: RE: Physicians that have not responded to 7-26 letter (with handwriting)		
DO212	09/18/03	10:44 AM	Email from L. Stevens to J. Lemieux re: FW: ACTION REQUIRED BY SEPTEMBER 26, 2003		
DO213	09/19/03	3:38 PM	Email from L. Stevens to J. Lemieux re: FW: ACTION REQUIRED BY SEPTEMBER 26, 2003		
DO214	09/22/03	8:52 AM	Email chain from D. Foreman to L. Stevens, L. Hedgpeth, cc'd to S. Shade, J. Lemieux re: RE: Removal of Dr. Ken Fujioka from GSK Speaker Event database		
DO215	09/23/03	4:21 PM	Email from L. Stevens to S. Shade, T. Thelen, C. Grant, D. Snyder, and J. Lemieux re: FW: GSK WBSR: Aldo Davico Interview memo and attachments		
DO216	10/01/03	8:10 AM	Email from J. Lemieux to L. Stevens re: FW: ACTION REQUIRED BY SEPTEMBER 26, 2003		
DO217	10/01/03	2:47 PM	Email from L. Stevens to J. Lemieux re: FW: Removal of Dr. Doni Middleman		
DO218	10/16/03	5:56 PM	Email from R. Williams to L. Frank, cc'd to L. Stockbridge, S. Saini, T. Abrams re: Wellbutrin SR Inquiry Letter		
DO219	10/17/03	8:28 AM	Email from L. Stevens to S. Shade, N. Reeves, M. Brown, J. Lemieux, D. Snyder, T. Thelen re: DDMAC Contact		
DO220	10/26/03	8:24 PM	Email from L. Stevens to T. Nichols re: RE:		
DO221	10/27/03	8:43 AM	Email from L. Stevens to S. Shade, J. Lemieux re: FW: [no subject]		
DO222	10/28/03		Memo from M. Brown and N. Reeves to L. Stevens re Mark Schwartz Interview Summary		
DO223	10/29/03	5:09 PM	Email from L. Stevens to J. Lemieux re: FW: Teleconference Slides		
DO224	10/31/03	9:34 AM	Email from S. Shade to D. Snyder re: Draft Letter to FDA		
DO225	11/19/03	1:55 PM	Email from J. Lemieux to L. Stevens, S. Shade re: List of 26 physicians - acknowledgment; Attaching 01/22/03 revised Response from Doctors		
DO226	01/06/04	8:48 AM	Email from L. Stevens to N. Reeves, cc'd to S. Shade, M. Brown, M. Jensen re: Re: GSK WBSR: memo summarizing GSK response FDA inquiry into Wellbutrin SR promotion attached; Attaching memorandum from M. Brown, N. Reeves to L. Stevens		
DO227	01/07/04		Hard copy of email from J. Lemieux to S. Shade forwarding Responses Regarding June 26, 2003 Letter to Doctors Wellbutrin Speaker Slide Set		

Page 27

Page 28

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0304	10/17/02	5:34 PM	Email from M. Brown to D. Snyder, T. Thelen re: Meeting		
D0305	10/17/02	6:29 PM	Email from T. Thelen to M. Brown, ccd to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, L. Stevens, S. Shade re: RE: Meeting		
D0306	10/21/02	4:13 PM	Email from J. Lemieux to T. Thelen, L. Stevens, S. Shade, J. Hetzel, D. Hanley, M. Brown, M. Jensen re: FDA Inquiry (with handwriting)		
D0307	10/22/02	10:31 AM	Email from J. Lemieux to T. Thelen, L. Stevens, S. Shade, J. Hetzel, D. Hanley, M. Brown, M. Jensen re: Updated: FDA Inquiry		
D0308	10/28/02	8:48 AM	Email from L. Stevens to J. Murray, T. Thelen, D. Snyder, M. Brown, ccd to S. Shade re: October 14, 2002		
D0309	10/28/02	9:59 AM	Email from M. Brown to M. Jensen re: FW: October 14, 2002: Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170		
D0310	10/28/02	4:41 PM	Email from L. Stevens to M. Jensen, ccd to M. Brown, D. Snyder, S. Shade, T. Thelen re: RE: FDA letter comments		
D0311	10/28/02	5:41 PM	Email from L. Stevens to M. Jensen, ccd to T. Thelen, M. Brown, D. Snyder, S. Shade re: RE: FDA letter comments		
D0312	10/29/02	3:51 AM	Email from T. Thelen to L. Stevens, ccd to J. Murray, D. Snyder, S. Shade, M. Brown re: FW: October 14, 2002: Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170		
D0313	10/29/02	6:29 AM	Email from J. Murray to L. Stevens, ccd to D. Snyder, S. Shade, T. Thelen re: Re: FW: October 14, 2002: Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170 (with track changes)		
D0314	10/29/02	9:15 AM	Email from L. Stevens, ccd to J. Murray, D. Snyder, S. Shade, M. Brown, M. Jensen re: October 14, 2002		
D0315	10/29/02	9:17 AM	Email from L. Stevens to M. Jensen re: FW: October 14, 2002		
D0316	10/29/02	10:04 AM	Email from M. Brown to D. Snyder, L. Stevens, T. Thelen, ccd to M. Jensen re: NY Times Article: Documents Show Effort to Promote Unproven Drug		
D0317	10/29/02	10:37 AM	Email from M. Brown to L. Stevens, T. Thelen, ccd to D. Snyder, M. Jensen re: Next Visit		
D0318	10/29/02	10:44 AM	Email from L. Stevens to M. Brown, L. Stevens, T. Thelen, ccd to D. Snyder, M. Jensen, S. Shade re: RE: Next Visit		
D0319	10/29/02	11:37 AM	Email from M. Bosch to L. Stevens, T. Thelen, ccd to D. Snyder, M. Jensen re: Next Visit		
D0320	10/29/02	11:43 AM	Email from M. Brown to L. Stevens, T. Thelen, ccd to D. Snyder, M. Jensen, S. Shade re: RE: Next Visit		
D0321	10/29/02	11:46 AM	Email from L. Stevens to D. Snyder, J. Murray, M. Jensen, M. Brown, S. Shade, T. Thelen re: Final Review of letter, Attaching draft letter to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS #11170		
D0322	10/29/02	12:43 PM	Email from M. Brown to lcs31072@gsk.com, L. Stevens, T. Thelen, ccd to D. Snyder, M. Jensen, S. Shade re: RE: Next Visit		
D0323	10/29/02	2:38 PM	Email from D. Snyder to L. Stevens, ccd to T. Thelen, S. Shade, M. Brown, M. Jensen, J. Murray re: Re: Final Review of letter, Attaching draft letter from L. Stevens NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS		
D0324	10/29/02		Email from L. Stevens to T. Thelen, S. Shade, D. Snyder, M. Brown, M. Jensen, J. Murray re: Final Review of letter, Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS		
D0325	10/30/02	1:10 PM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0326	10/30/02	2:10 PM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0327	10/30/02	6:46 PM	Email from L. Stevens to M. Brown, ccd S. Shade, D. Snyder, T. Thelen, M. Jensen re: RE: [no subject]		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0328	10/31/02	8:49 AM	Email from L. Stevens to M. Brown, ccd to S. Shade, D. Snyder, T. Thelen, M. Jensen re: RE: [no subject]		
D0329	11/04/02	11:05 AM	Email from M. Jensen to L. Stevens, T. Thelen, S. Shade, ccd to M. Brown, D. Snyder re: Information Request Letters;		
D0330	11/04/02	12:03 PM	Attaching letter from L. Stevens re: Request to Physicians for Promotional Materials Relating to Wellbutrin SR (bupropion HCI)		
D0331	11/04/02	12:15 PM	Email from J. Lemieux to M. Brown, M. Jensen re: Scheduling GSK Interviews		
D0332	11/04/02	12:58 PM	Email from J. Lemieux to M. Jensen re: FW: Scheduling GSK interviews	APR 29 2011	APR 29 2011
D0333	11/04/02	12:58 PM	Attaching draft information request letters (with track changes)		
D0334	11/04/02	4:34 PM	Email from L. Stevens to M. Jensen, T. Thelen, S. Shade, ccd to M. Brown, D. Snyder re: RE: Information Request Letters; Attaching letter from L. Stevens re: Wellbutrin SR (bupropion HCI Sustained-Release Tablets) - Request for Presentation		
D0335	11/04/02	4:34 PM	Email from S. Shade to L. Stevens, M. Jensen, T. Thelen, ccd to M. Brown, D. Snyder re: RE: Information Request Letters; Attaching draft GSK letters to sales representatives and doctors sales representatives requesting presentation materials		
D0336	11/04/02	4:34 PM	Attaching draft information request letters (with track changes)		
D0337	11/04/02	8:38 PM	Email from S. Shade to L. Stevens, M. Jensen, T. Thelen, D. Snyder re: re: Information Request Letters; Attaching letter from L. Stevens re: Wellbutrin SR (bupropion HCI Sustained-Release Tablets) - Request for Presentation Materials (with track		
D0338	11/05/02	12:39 PM	Email from L. Stevens to M. Jensen, T. Thelen, M. Brown, D. Snyder, S. Shade re: RE: Information Request Letters - Action Needed		
D0339	11/05/02	4:11 PM	Email from M. Jensen to L. Stevens, ccd to T. Thelen, D. Snyder, S. Shade, J. Lemieux, M. Brown re: Q & A's, Interview Schedule	APR 29 2011	APR 29 2011
D0340	11/06/02	4:03 PM	Email from L. Stevens to D. Snyder, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: Lesley Frank, Attaching 11/5/02 Draft Letter to doctors and sales reps		
D0341	11/06/02	4:04 PM	Email from L. Stevens to D. Snyder, S. Shade, T. Thelen, M. Jensen, M. Brown, J. Lemieux re: Lesley Frank, Attaching draft GSK communications to sales representatives and doctors requesting presentation materials		
D0342	11/06/02	4:04 PM	Email from L. Stevens to D. Snyder, S. Shade, T. Thelen, M. Jensen, M. Brown, J. Lemieux re: Lesley Frank, Attaching draft letter from L. Stevens re: Request to Physicians for Presentation Materials Relating to Wellbutrin SR (bupropion HCI) Sustained-	MAY 3 2011	MAY 3 2011
D0343	11/06/02	4:50 PM	Email from D. Snyder to L. Stevens, ccd to S. Shade, T. Thelen, M. Jensen, M. Brown, J. Lemieux re: Re: Lesley Frank, Attaching Draft Letter from L. Stevens to sales representatives and doctors requesting presentation materials relating to		
D0344	11/06/02	4:51 PM	Email from D. Snyder to L. Stevens, ccd to S. Shade, T. Thelen, M. Jensen, M. Brown, jak45847@gsk.com re: Lesley Frank, Attaching draft letter from L. Stevens to sales representatives re: Request to Physicians for Presentation Materials Relating to		
D0345	11/08/02	6:32 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: DRAFT 11/07/02		
D0346	11/11/02	11:47 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]; Attaching Draft Letter to sales reps and doctors requesting presentation materials and letter to D. Ryan (with		
D0347	11/12/02	7:07 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]; Attaching Draft Questions & Answers for GSK Letters to Physicians and Sales Representatives Requesting		
D0348	11/12/02	7:07 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]; Attaching Draft Questions & Answers for GSK Letters to Physicians and Sales Representatives Requesting		
D0349	11/12/02	7:07 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0350	11/12/02	10:29 AM	Email from S. Shade to M. Brown, M. Jensen re: Next Week		
D0351	11/12/02	11:01 AM	Email from M. Jensen to L. Stevens, ccd to M. Brown re: RE: [no subject]		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0352	11/12/02	7:06 PM	Email from L. Stevens to S. Hull, L. Gonzalez, D. Guterman, J. Miller, M. Murkes, M. Martinson, J. Murray, V. Stowe, B. Judd, T. Caridi, T. Poe, E. Collins, D. Wheadon, ccd to S. Shade, J. Lemieux, J. Hetzel, M. Werner re: Communications regarding	May 3 2011	May 3 2011
D0353	11/13/02	7:48 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: T/C with Frank this morning		
D0354	11/13/02	2:32 PM	Email from S. Shade to M. Brown, M. Jensen, ccd to L. Stevens re: [no subject]. Attaching interviewee information		
D0355	11/14/02	7:30 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen [no subject] (with handwriting). Attaching GSK Letters to Physicians and Sales Representatives Requesting Promotional		
D0356	11/15/02	5:00 PM	Email from S. Shade to M. Brown, M. Jensen re: org charts		
D0357	11/15/02	5:15 PM	Email from M. Brown to S. Shade, M. Jensen re: RE: org charts		
D0358	11/15/02	6:24 PM	Failed communication report for fax from S. Shade to M. Brown, M. Jensen. Attaching organization charts and screen shots of GSK eHR PeopleView website		
D0359	11/15/02	7:30 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]. Attaching GSK Letters to Physicians and Sales Representatives Requesting Promotional Information Draft Questions & Fax cover sheet from S. Shade to M. Brown, M. Jensen		
D0360	11/15/02				
D0361	11/16/02	4:31 PM	Email from L. Stevens to M. Jensen, D. Snyder, S. Shade, T. Thelen, J. Lemieux, M. Brown re: RE: L. Frank. Attaching draft letter re: Wellbutrin SR		
D0362	11/17/02	6:03 PM	Email from M. Jensen to S. Shade, M. Brown re: RE: org charts		
D0363	11/20/02	10:26 AM	Fax from L. Stevens to M. Brown, M. Jensen. Attaching letter from S. Saini to M. Martinson re: NDA 20-358 Wellbutrin SR (bupropion HCl sustained-release tablets) MACMIS #11170		
D0364	11/20/02	5:11 PM	Email from M. Brown to L. Stevens, ccd to M. Jensen re: Redacted Letter to Donna Ryan		
D0365	11/20/02	6:17 PM	Email from L. Stevens to M. Brown, ccd to M. Jensen re: RE: Redacted Letter to Donna Ryan		
D0366	11/20/02	7:38 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen		
D0367	11/21/02	11:40 AM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade re: Dr. Ryan Interview today. Attaching letter from L. Stevens to D. Ryan re: FDA Inquiry OF GlaxoSmithKline dated 11/21/02		
D0368	11/21/02	11:43 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen, ccd to M. Jackson re: [no subject]		
D0369	11/21/02	11:48 AM	Email from M. Brown to D. Hanley, J. Hetzel, M. Jensen, J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Jackson re: RE: [no subject]		
D0370	11/21/02	12:21 PM	Email from L. Stevens to M. Brown, D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, S. Shade, D. Snyder, T. Thelen, ccd to M. Jackson re: RE: [no subject]		
D0371	11/21/02	6:03 PM	Email from L. Stevens to M. Jensen, M. Brown re: FW: Pradko 11-15-02 Notes. Attaching "NEURORECEPTOR BASIS OF INITIAL ANTIDEPRESSANT CHOICE"		
D0372	11/22/02	8:59 AM	Email from T. Thelen to L. Stevens, S. Shade, M. Brown, M. Jensen re: Tuesday's conference call		
D0373	11/22/02	9:01 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: RE: Tuesday's conference call		
D0374	11/23/02	8:13 AM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: FW: [no subject]		
D0375	12/02/02	11:09 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen (with handwritten notes)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0376	12/02/02	11:09 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0377	12/02/02	5:12 PM	Email from M. Jensen to L. Stevens, ccd to M. Brown, S. Shade, D. Snyder, T. Thelen re: Wolkowitz Letter, Attaching draft letter to O. Wolkowitz (with track changes)		
D0378	12/02/02	5:12 PM	Email from M. Jensen to L. Stevens, ccd to T. Thelen, D. Snyder, S. Shade, M. Brown re: Wolkowitz Letter, Attaching letter to Owen (with track changes)		
D0379	12/03/02	11:11 AM	Email from L. Stevens to M. Jensen, M. Brown re: [no subject]		
D0380	12/03/02	11:26 AM	Email from M. Brown to L. Stevens, M. Jensen re: RE: [no subject]		
D0381	12/03/02	12:16 PM	Email from L. Stevens to M. Brown, M. Jensen, T. Thelen, S. Shade re: RE: [no subject]		
D0382	12/03/02	6:56 PM	Email from M. Jensen to L. Stevens, ccd to S. Shade, M. Brown re: Document Requests During Interviews, Attaching Summary of Documents and Information Requests from Interviews (11/18/02 and 11/19/02)		
D0383	12/03/02	6:56 PM	Email from M. Jensen to L. Stevens, ccd to S. Shade, M. Brown re: Document Requests During Interviews, Attaching Modified List of Document Requests from November GSK Interviews (11/18/02 and 11/19/02) (with track changes)		
D0384	12/04/02	7:50 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen, ccd to M. Werner re: WSJ.com - When Doctors Go to Class Industry Often Foots the Bill, Hm! (without attachment)		
D0385	12/04/02	11:45 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: WBSR Teleconference Sprint Line		
D0386	12/06/02	1:19 PM	Email from M. Jensen to L. Stevens, ccd to T. Thelen, D. Snyder, S. Shade, M. Brown, N. Reeves re: RMS Letters, Attaching Draft Letter re: Wellburrin SR (bupropion HCl) Sustained-Release Tablets) - Approved Presentation Slides for PRIDE Speakers		
D0387	12/06/02	3:26 PM	Email from L. Stevens to M. Jensen, M. Brown re: FW: presentations		
D0388	12/07/02	4:30 PM	Email from L. Stevens to J. Millar re: RE: Speakers/Speaker Programs-- Please take a look and reply by end of day on Friday		
D0389	12/09/02	12:28 PM	Email from M. Jensen to S. Shade, ccd to L. Stevens, M. Brown re: Pradko Letter, Attaching draft letter to J. Pradko (with track changes)		
D0390	12/09/02	12:28 PM	Email from M. Jensen to S. Shade, ccd to D. Snyder, M. Brown re: Pradko Letter, Attaching letter from J. Millar to J. Pradko dated 12/09/02		
D0391	12/09/02	12:36 PM	Email from M. Jensen to L. Stevens re: RE: RMS follow-up with Physicians- Draft proposal		
D0392	12/09/02	1:23 PM	Email from S. Shade to M. Jensen, ccd to L. Stevens, M. Brown re: RE: Pradko Letter		
D0393	12/09/02	2:25 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen, ccd to J. Hetzel, J. Lemieux, D. Hanley, D. Snyder re: Updated: WBSR Teleconference Sprint Line		
D0394	12/09/02	2:43 PM	Email from L. Stevens to M. Jensen, ccd to M. Brown, S. Shade re: RE: Pradko Letter		
D0395	12/09/02	3:20 PM	Email from L. Stevens to M. Jensen re: RE: RMS follow-up with Physicians- Draft proposal		
D0396	12/09/02	4:40 PM	Email from L. Stevens to M. Jensen, M. Brown, ccd to S. Shade re: RE: Pradko Letter		
D0397	12/09/02	5:12 PM	Email from M. Jensen to L. Stevens, M. Brown, ccd to S. Shade re: RE: Pradko Letter		
D0398	12/11/02	10:52 AM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, T. Thelen re: FW: Privileged & Confidential: Product Work Excel RMS listing WLBCITRS75a.xls, Attaching spreadsheet		
D0399	12/11/02	11:46 AM	Email from L. Stevens to M. Jensen, M. Brown re: PhRMA's 200Code%20approved%204-18-02 doc, Attaching PhRMA Code on Interactions with Healthcare Professionals		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0400	12/11/02	12:28 PM	Email from M. Jensen to D. Hanley, J. Hetzel, J. Lemieux, S. Shade, D. Snyder, L. Stevens, T. Thelen, ccd to M. Brown re: RE: Privileged & Confidential: Product Work: Excel RMS listing: W1BCTRS75a.xls		
D0401	12/11/02	2:10 PM	Email from M. Brown to L. Stevens, M. Jensen, S. Shade re: Availability Next Week		
D0402	12/11/02	4:16 PM	Email from M. Jensen to L. Stevens, S. Shade, D. Hanley, J. Hetzel, J. Lemieux, ccd to M. Brown re: CD Rom's		
D0403	12/11/02		Draft memorandum re: RE: Wellbutrin SR (bupropion HCI Sustained-Release Tablets) -- Presentation Slides for P.R.I.D.E. Speakers		
D0404	12/12/02		Letter from J. Lemieux to M. Jensen		
D0405	12/13/02	1:28 PM	Email from L. Stevens to M. Brown re: [no subject]		
D0406	12/15/02	6:58 PM	Email from L. Stevens to S. Shade, M. Jensen, M. Brown re: Teleconference with Dr. Clayton		
D0407	12/17/02	3:27 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0408	12/17/02	4:49 PM	Email from S. Shade to D. Snyder, J. Lemieux, M. Brown, M. Jensen, T. Thelen, ccd to L. Stevens re: Revised Draft Response to Quest. 14, Attaching 12/15/02 draft response to Question 14		
D0409	12/18/02	5:35 PM	Email from M. Brown to L. Stevens, S. Shade, ccd to M. Jensen, N. Reeves, T. Thelen, D. Snyder, D. Hanley, J. Lemieux re: Revised Response: Attaching 12/18/02 draft letter from L. Frank Re: NDA 20-358 Wellbutrin SR (bupropion HCI)		
D0410	12/18/02	5:35 PM	Email from M. Brown to L. Stevens, S. Shade, ccd to M. Jensen, N. Reeves, T. Thelen, D. Snyder, D. Hanley, J. Lemieux re: Revised Response: Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI) Sustained		
D0411	12/19/02	11:40 AM	Email from M. Brown to L. Stevens, S. Shade, ccd to D. Snyder, T. Thelen, J. Hetzel, J. Lemieux, D. Hanley, M. Jensen, N. Reeves re: Revised Letter, Attaching draft letter from L. Stevens to L. Frank re: NDA 20-358 Wellbutrin SR (bupropion HCI)		
D0412	12/19/02	2:08 PM	Fax from L. Stevens to M. Brown, Attaching roundtable discussion invitation (with handwriting), various printouts (with handwriting)		
D0413	12/19/02	5:52 PM	Email from N. Reeves to S. Shade, ccd to L. Stevens, M. Brown, M. Jensen re: Request for 2001 WBSR Operating and Strategy Plans		
D0414	12/20/02	2:27 PM	Email from L. Stevens to D. Hanley, D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, T. Thelen re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/SUBJECT TO WORK PRODUCT DOCTRINE	NOV 3 2011	NOV 3 2011
D0415	12/29/02	6:42 PM	Email from S. Shade to N. Reeves, ccd to L. Stevens, M. Brown, M. Jensen re: RE: Request for 2011 WBSR Operating and Strategy Plans		
D0416	01/14/03		Letter from J. Lemieux to M. Jensen		
D0417	01/15/03	6:30 PM	Email from S. Shade to M. Brown, M. Jensen re: Policy on Speaker Events - Additional PROPOSED_DRAFT Changes msg (without attachment)		
D0418	01/16/03	8:39 AM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0419	01/16/03	10:11 AM	Email from M. Brown to S. Shade, M. Jensen, ccd to N. Reeves re: RE: [no subject]		
D0420	01/16/03	10:15 AM	Email from N. Reeves to S. Shade, ccd to M. Brown re: RE: contact info for Nikki Reeves		
D0421	01/21/03	12:45 PM	Email from M. Brown to L. Stevens, J. Lemieux, S. Shade, ccd to M. Jensen, N. Reeves re: RE: Trained Speaker [sic] who have spoken		
D0422	01/21/03	12:51 PM	Email from L. Stevens to M. Brown re: RE: Trained Speaker [sic] who have spoken (with handwriting)		
D0423	01/24/03		Letter from J. Lemieux to M. Jensen [no subject] (without attachments)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0424	01/27/03	9:57 AM	Email from M. Brown to L. Stevens, cc'd to M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION SUBJECT TO ATTORNEY WORK PRODUCT DOCTRINE		
D0425	01/27/03	10:08 AM	Email from L. Stevens to M. Brown, cc'd to S. Shade, J. Lemieux, D. Snyder, M. Jensen, N. Reeves re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION SUBJECT TO ATTORNEY WORK PRODUCT DOCTRINE		
D0426	01/27/03	10:28 AM	Email from M. Brown to L. Stevens, cc'd to M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION SUBJECT TO ATTORNEY WORK PRODUCT DOCTRINE		
D0427	01/27/03		Memorandum from L. Stevens and S. Shade to M. Brown, M. Jensen, N. Reeves re: Teleconference with FDA on January 21, 2003		
D0428	01/27/03		Memo from S. Shade M. Brown, M. Jensen, N. Reeves, cc'd to GSK File re: Teleconference with FDA on January 21, 2003		
D0429	01/29/03	8:02 AM	Email from L. Stevens to M. Jensen, M. Brown, N. Reeves, S. Shade, cc'd to J. Lemieux re: FW: [no subject]		
D0430	01/29/03	8:02 AM	Email from L. Stevens to M. Jensen, M. Brown, N. Reeves, S. Shade, cc'd to J. Lemieux re: FW: (with handwritten note)		
D0431	01/29/03	10:57 AM	Email from J. Lemieux to L. Stevens, M. Jensen, M. Brown, N. Reeves re: Trained Speakers		
D0432	01/29/03	12:39 PM	Email from J. Lemieux to L. Stevens, M. Jensen, M. Brown, N. Reeves, S. Shade re: RE: (with handwriting)		
D0433	01/29/03	12:39 PM	Email from J. Lemieux to L. Stevens, M. Jensen, M. Brown, N. Reeves, S. Shade re: RE: [no subject]		
D0434	01/29/03	1:50 PM	Email from M. Brown to J. Lemieux, L. Stevens, M. Jensen, N. Reeves, S. Shade re: RE: [no subject]		
D0435	01/29/03	2:17 PM	Email from J. Lemieux to M. Brown, L. Stevens, M. Jensen, N. Reeves, S. Shade re: RE: [no subject]		
D0436	01/29/03	3:57 PM	Email from M. Brown to J. Lemieux, L. Stevens, M. Jensen, N. Reeves, S. Shade re: RE: [no subject]		
D0437	01/29/03	4:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens, J. Lemieux re: Anderson		
D0438	01/29/03	5:37 PM	Fax from S. Shade to M. Brown, M. Jensen, N. Reeves, Attaching fax from D. Bukunya to List re: Bupropion SR significantly enhances weight loss: A 24-week double-blind, placebo-controlled trial with placebo group randomized to bupropion SR during		
D0439	01/29/03	5:52 PM	Cover page of fax from S. Shade to M. Brown, M. Jensen, N. Reeves		
D0440	01/29/03	5:54 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: [no subject]		
D0441	01/30/03	3:26 PM	Email from S. Shade to M. Jensen, N. Reeves re: Presentations; Attaching Review of Doctor Responses dated 01/30/03		
D0442	01/31/03	11:24 AM	Email from M. Jensen to D. Snyder, L. Stevens, cc'd to M. Brown, N. Reeves, S. Shade, T. Thelen re: Revised Ryan Narrative; Attaching 1/31/03 draft Dr. Donna Ryan Narrative		
D0443	01/31/03	11:32 AM	Email from S. Shade to M. Jensen re: RE: Revised Ryan Narrative		
D0444	01/31/03	11:45 AM	Email from M. Jensen to S. Shade re: RE: Revised Dr. Donna Ryan Narrative		
D0445	01/31/03	6:37 PM	Email from N. Reeves to J. Lemieux, cc'd to M. Brown, M. Jensen, L. Stevens, S. Shade re: Question re: physician speaker numbers (with handwritten notes)		
D0446	02/03/03	4:33 PM	Email from J. Lemieux to N. Reeves, cc'd to M. Brown, M. Jensen, L. Stevens, S. Shade re: RE: Question re: physician speaker numbers		
D0447	02/03/03	5:25 PM	Email from M. Brown to J. Lemieux, N. Reeves, cc'd to M. Jensen, L. Stevens, S. Shade re: RE: Question re: physician speaker numbers		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0448	02/04/03	2:23 PM	Email from J. Lemieux to M. Brown, N. Reeves, cc'd to M. Jensen, L. Stevens, S. Shade re: RE: Question re: physician speaker numbers (with handwriting)		
D0449	02/04/03	2:25 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens re: Interview w/ J. Warnock		
D0450	02/04/03	2:38 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, L. Stevens, J. Lemieux, J. Hetzel re: questionnaires		
D0451	02/04/03	5:56 PM	Email from M. Jensen to L. Stevens, S. Shade, cc'd to J. Lemieux, M. Brown, N. Reeves re: FW: Dr. Presentations, K&S Review		
D0452	02/04/03		Letter from J. Lemieux to M. Jensen		
D0453	02/05/03	2:42 PM	Email from S. Shade to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, D. Snyder re: RE: Dr. Ryan Narrative; Attaching draft Dr. Donna Ryan Narrative Wellbutrin SR, FDA Information Request Responsive to Questions 2, 4, 5.		
D0454	02/05/03	3:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, J. Lemieux, J. Hetzel, D. Snyder, cc'd to L. Stevens re: Teleconference Agenda (with handwritten notes)		
D0455	02/05/03	3:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, J. Lemieux, J. Hetzel, D. Snyder, cc'd to L. Stevens re: Teleconference Agenda (with handwritten notes); Attaching handwritten notes		
D0456	02/05/03	3:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, J. Lemieux, J. Hetzel, D. Snyder, cc'd to L. Stevens re: Teleconference Agenda (with handwritten notes)		
D0457	02/05/03	3:28 PM	Email from S. Shade to D. Snyder, J. Hetzel, J. Lemieux, M. Brown, N. Reeves, cc'd to L. Stevens re: Teleconference Agenda		
D0458	02/05/03	3:28 PM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, J. Lemieux, J. Hetzel, D. Snyder, cc'd to L. Stevens re: Teleconference Agenda (with handwriting)		
D0459	02/05/03	3:51 PM	Email from M. Brown to J. Lemieux, S. Shade, D. Snyder, L. Stevens, cc'd to M. Jensen, N. Reeves re: 2253 Search		
D0460	02/05/03	3:52 PM	Email from M. Brown to L. Stevens, J. Lemieux, S. Shade, D. Snyder, cc'd to M. Jensen, N. Reeves re: 2253 Search (with handwritten notes)		
D0461	02/05/03	3:52 PM	Email from M. Brown to L. Stevens, J. Lemieux, S. Shade, D. Snyder, cc'd to M. Jensen and N. Reeves re: 2253 Search (with handwritten notes)		
D0462	02/05/03		Letter from J. Lemieux to M. Jensen (no subject and without enclosures)		
D0463	02/06/03	1:53 PM	Email from M. Jensen to S. Shade, cc'd to L. Stevens, M. Brown, N. Reeves re: Ryan Comments		
D0464	02/06/03	2:02 PM	Email from S. Shade to M. Jensen re: RE: Ryan Comments		
D0465	02/10/03	10:35 AM	Email from J. Hetzel to L. Stevens, S. Shade, M. Brown, M. Jensen, N. Reeves, J. Lemieux, D. Snyder re: 9/18/01 Presentation by Dr. Jim Anderson and Dr. Reynolds		
D0466	02/10/03	10:35 AM	Email from J. Hetzel to L. Stevens, S. Shade, M. Brown, M. Jensen, N. Reeves, J. Lemieux, D. Snyder re: 9/18/01 Presentation by Dr. Jim Anderson and Dr. Reynolds		
D0467	02/10/03	2:56 PM	Email from M. Brown to J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder, L. Stevens re: RE: 9/18/01 Presentation by Dr. Jim Anderson and Dr. Reynolds		
D0468	02/10/03	2:57 PM	Email from M. Brown to J. Hetzel, L. Stevens, S. Shade, M. Jensen, N. Reeves, J. Lemieux, D. Snyder re: RE: 9/18/01 Presentation by Dr. Jim Anderson and Dr. Reynolds (with handwriting)		
D0469	02/10/03	4:38 PM	Email from L. Stevens to M. Brown, D. Snyder, M. Jensen, J. Hetzel, J. Lemieux, N. Reeves, S. Shade re: RE: 9/18/01 Presentation by Dr. Jim Anderson and Dr. Reynolds		
D0470	02/11/03	12:21 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT (without attachment)		
D0471	02/11/03	12:29 PM	Email from M. Brown to J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder, L. Stevens re: RE: PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION/ ATTORNEY WORK PRODUCT		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0472	02/11/03	12:44 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL ATTORNEY WORK PRODUCT (without attachment)		
D0473	02/11/03	1:09 PM	Email from S. Shade to M. Jensen re: [no subject]		
D0474	02/11/03	2:09 PM	Email from M. Jensen to S. Shade, cc'd to N. Reeves, M. Brown re: Presentation Review		
D0475	02/11/03	2:27 PM	Email from N. Reeves to S. Shade, M. Jensen, cc'd to M. Brown re: RE: Presentation Review		
D0476	02/11/03	2:40 PM	Email from S. Shade to M. Jensen, N. Reeves, cc'd to M. Brown re: RE: Presentation Review		
D0477	02/12/03	4:47 AM	Email from M. Brown to S. Shade, cc'd to M. Jensen re: 2253		
D0478	02/12/03	9:16 AM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens re: Bupropion Slides; Attaching article by J. Anderson, "Bupropion SR Enhances Weight Loss: A 48-Week Double-Blind, Placebo-Controlled Trial", Speaker Training Slides		
D0479	02/12/03	10:36 AM	Email from M. Jensen to S. Shade re: RE: Bupropion Slides		
D0480	02/12/03	12:22 PM	Email from S. Shade to M. Jensen re: RE: Bupropion Slides		
D0481	02/12/03	5:30 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens, S. Shade re: RE: Speaker Utilization		
D0482	02/12/03	5:42 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves re: RE: Ryan & Anderson e-mail addresses		
D0483	02/12/03	5:56 PM	Email from S. Shade to M. Brown, cc'd to M. Jensen re: RE: 2253		
D0484	02/12/03	6:16 PM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves re: RE: Screen Shots for #75 fulfillment update		
D0485	02/12/03	6:32 PM	Email from J. Lemieux to M. Brown, L. Stevens, J. Hetzel, M. Jensen, N. Reeves, S. Shade, D. Snyder re: Breakdown of # of RMS trained docs that attended PRIDE training		
D0486	02/12/03	6:55 PM	Fax from J. Lemieux to M. Jensen re: PRIDE topics; Attaching 2001 and 2002 Wellbutrin SR PRIDE Program Representative Registration forms		
D0487	02/12/03		Fax from J. Lemieux to M. Jensen re: PRIDE topics; Attaching 2001 Wellbutrin SR PRIDE Program Representative Registration Form, 2002 PRIDE Program for Wellbutrin SR Representative Registration Form		
D0488	02/13/03	9:57 AM	Email from M. Brown to J. Lemieux, M. Jensen, N. Reeves, cc'd to L. Stevens, S. Shade re: RE: Speaker Utilization		
D0489	02/13/03	10:29 AM	Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens, S. Shade re: RE: Speaker Utilization		
D0490	02/13/03	11:56 AM	Email from M. Brown to J. Lemieux, M. Jensen, N. Reeves, cc'd to L. Stevens, S. Shade re: RE: Speaker Utilization		
D0491	02/13/03		Letter from J. Lemieux to M. Jensen [no subject]; Attaching list of documents produced to FDA		
D0492	02/14/03	1:50 PM	Email from M. Brown to L. Stevens, J. Hetzel, J. Lemieux, M. Jensen, N. Reeves, S. Shade, D. Snyder re: RE: Question 1 PRIVILEGED/CONFIDENTIAL ATTORNEY WORK PRODUCT		
D0493	02/14/03	1:56 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED/CONFIDENTIAL		
D0494	02/19/03	8:30 AM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, cc'd to N. Reeves, M. Jensen re: ADA Presentation of Dr. Anderson; Attaching Dr. Anderson's presentation materials "Bupropion SR Significantly Enhances Weight Loss When Used With a		
D0495	02/20/03	3:06 PM	Email from J. Lemieux to L. Stevens, J. Hetzel, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: Question # 12 PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0496	02/20/03	3:33 PM	Email from M. Jensen to L. Stevens, J. Lemieux, J. Hetzel, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: Question # 12 PRIVILEGED/CONFIDENTIAL LEGAL COMMUNICATION		
D0497	02/20/03	4:01 PM	Email from N. Reeves to L. Stevens, S. Shade, J. Hetzel, D. Snyder, J. Lemieux, ccd to M. Brown, M. Jensen re: Revised narrative for Dr. Anderson attached. Attaching 02/20/03 draft narrative for Dr. Anderson		
D0498	02/26/03	2:58 PM	Email from K. Kiburn to M. Brown, M. Jensen, N. Reeves, ccd to S. Shade re: re: 4:00 Teleconference on Thursday 2/27/03-WBSR-Question 1 Response to FDA		
D0499	02/26/03	3:18 PM	Email from S. Shade to L. Stevens, ccd to K. Kiburn re: FW: re: Teleconference on Thursday 2/27/03- WBSR-Question 1 Response to FDA		
D0500	02/26/03	4:21 PM	Email from L. Stevens to M. Jensen, N. Reeves, M. Brown re: FW: re: Wellbutrin FDA Response to Question 1-Teleconference @ 4:00 PM	MAY 5 2011	
D0501	02/28/03	8:53 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: FW: Follow up: Attaching July 2002 "Profiles in Depression"	MAY 5 2011	
D0502	02/28/03	8:54 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: FW: Follow up: Attaching 08/2002 Profiles in Depression article by Dr. M. Agronin, "Managing Depression-Associated Weight Gain", 07/2002		
D0503	03/05/03	10:31 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: [no subject]		
D0504	03/05/03	3:03 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves, D. Clark re: Screen Shots & Slide Kit 75; Attaching draft 02/25/03 memorandum from M. Clark to M. Brown, M. Jensen, N. Reeves re: Retrieval of GSK Kit		
D0505	03/05/03	3:03 PM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Brown, D. Clark, N. Reeves re: Screen Shots & Slide Kit 75; Attaching memorandum from D. Clark to M. Brown, J. Jensen, N. Reeves re: Retrieval of GSK Kit 75 dated		
D0506	03/05/03	4:13 PM	Email from J. Lemieux to M. Jensen, L. Stevens, S. Shade, ccd to M. Brown, N. Reeves re: RE: RMS Fulfillment		
D0507	03/05/03	6:54 PM	Email from S. Shade to D. Snyder, J. Lemieux, L. Stevens, M. Brown, M. Jensen, N. Reeves re: Poster: Attaching poster of Bupropion SR versus Placebo Comparison of Depressive Symptoms and Weight Loss in Obese Patients with a History of Major		
D0508	03/05/03	8:03 PM	Email from M. Jensen to L. Stevens, D. Snyder, S. Shade, J. Lemieux, ccd to M. Brown, N. Reeves, D. Clark re: Screen Shots & Slide Kit 75; Attaching February 19, 2003 Memorandum re: Comparison between GSK screen shots and training attendees		
D0509	03/05/03	8:57 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: SE: Database Rev4 - 05 05 03 xls PRIVILEGED/CONFIDENTIAL; Attaching spreadsheets		
D0510	03/05/03		Letter from J. Lemieux to M. Jensen		
D0511	03/06/03	10:25 AM	Email from S. Shade to M. Brown, M. Jensen, N. Reeves, ccd to L. Stevens, J. Lemieux re: 2253 submissions of WBSR		
D0512	03/06/03	2:20 PM	Email from J. Lemieux to D. Clark, ccd to M. Jensen re: RE: Susan Lizarald RMS Response		
D0513	03/06/03	3:51 PM	Email from L. Stevens to J. Lemieux re: FW: Privileged & Confidential: Product Work: Wellbutrin SR Speaker [sic] training information, Attaching Don Frailey information		
D0514	03/06/03	3:57 PM	Email from J. Lemieux to D. Clark, ccd to M. Jensen re: RE: Don Frailey RMS Response; Attaching list of physicians and history of contact		
D0515	03/07/03	11:52 AM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, ccd to J. Hetzel, J. Lemieux, M. Jensen, N. Reeves re: RE: SE: Database Rev4 - 03 05 03 xls PRIVILEGED/CONFIDENTIAL; Attaching GlaxoSmithKline Speaker Event Database -		
D0516	03/07/03	2:06 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: SE: Database Rev4 - 03 05 03 xls PRIVILEGED/CONFIDENTIAL; Attaching memorandum from D. Tulip to NeuroHealth RVPs, ccd to L. Stevens		
D0517	03/07/03	2:47 PM	Email from L. Stevens to A. Kirsch re: [no subject]; Attaching spreadsheet of events and sales representative responsible; 3/7/03 Memo from L. Stevens to A. Kirsch re: Coaching and Counseling Speaking Points for RVPs		
D0518	03/07/03	5:10 PM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: Comparison between privileged/confidential; Attaching memorandum from D. Clark to M. Brown, M. Jensen, N. Reeves re: Screen Shot		
D0519	03/10/03	10:47 AM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Brown, D. Clark, N. Reeves re: Screen Shot Databases		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0520	03/10/03	11:22 AM	Email from S. Shade to L. Stevens, D. Snyder, J. Lemieux, M. Brown, M. Jensen, N. Reeves re: RE: [no subject]		
D0521	03/10/03		Letter from J. Lemieux to M. Jensen [no subject] (without attachments)		
D0522	03/11/03	3:27 PM	Email from M. Brown to S. Shade, ccd to M. Jensen, N. Reeves re: Conf Call		
D0523	03/11/03	4:51 PM	Email from S. Shade to M. Brown, L. Stevens, D. Snyder, J. Lemieux, ccd to M. Jensen, N. Reeves re: RE: Conf Call		
D0524	03/11/03	4:51 PM	Email from S. Shade to M. Brown, L. Stevens, D. Snyder, J. Lemieux, ccd to M. Jensen, N. Reeves re: RE: Conf Call (with handwriting)		
D0525	03/14/03	11:46 AM	Email from J. Lemieux to J. Lemieux, S. Shade, M. Brown, L. Stevens, D. Snyder, ccd to M. Jensen, N. Reeves, J. Hetzel re: RE: Conf Call		
D0526	03/15/03		Fax from O. Wolkowitz to L. Stevens; Attaching evaluations		
D0527	03/15/03		Fax from O. Wolkowitz to L. Stevens; Attaching speaker evaluations from GlaxoSmithKline-sponsored Medical Work Conferences programs (with handwritten notes requesting faxing to M. Brown)		
D0528	03/17/03	11:17 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder		
D0529	03/18/03	1:25 PM	Email from M. Jensen to J. Lemieux, S. Shade, D. Snyder, L. Stevens, ccd to M. Brown, D. Clark, N. Reeves re: Updated Screen Shots/Trainees and RMS Slide Kit Retrieval Memos; Attaching memorandum from D. Clark to M. Brown, M. Jensen, N. Reeves		
D0530	03/18/03		Letter from J. Lemieux to M. Jensen [no subject] (without attachments)		
D0531	03/19/03	12:20 PM	Email from M. Brown to L. Stevens, ccd to S. Shade, J. Lemieux, N. Reeves, M. Jensen re: Wolkowitz Call Availability		
D0532	03/19/03		Letter from J. Lemieux to M. Jensen		
D0533	03/19/03		Letter from J. Lemieux to M. Jensen [no subject]; Attaching detailed screen shots for slide set 75 (with handwriting)		
D0534	03/21/03	4:38 PM	Email from L. Stevens for M. Brown, ccd to S. Shade, J. Lemieux, N. Reeves, M. Jensen re: RE: Wolkowitz Call Availability		
D0535	03/21/03	5:39 PM	Email from L. Stevens to M. Brown, ccd to S. Shade, J. Lemieux, N. Reeves, M. Jensen re: RE: Wolkowitz Call Availability		
D0536	03/25/03	4:48 PM	Email from L. Stevens to S. Shade, M. Jensen, M. Brown, ccd to J. Lemieux re: FW: Times for talk		
D0537	03/26/03	4:13 PM	Email from L. Stevens to N. Reeves, ccd to M. Brown, M. Jensen, J. Lemieux re: RE: FDA submission letter -- electronic copy PRIVILEGED/CONFIDENTIAL, LEGAL COMMUNICATION; Attaching letter from L. Stevens to L. Frank re: NDA 20-358		
D0538	03/27/03	12:29 PM	Email from L. Stevens to N. Reeves, ccd M. Brown, M. Jensen re: PRIVILEGED/CONFIDENTIAL; Attaching draft letter from L. Stevens to J. Anderson re: J. Anderson's assistance to develop responses to the FDA		
D0539	03/27/03	4:28 PM	Email from L. Stevens to N. Reeves, M. Jensen, M. Brown, ccd to S. Shade, J. Lemieux re: FW: SIB Information		
D0540	03/27/03	4:56 PM	Fax from L. Stevens to M. Brown re: Dr. Wolkowitz; Attaching fax from O. Wolkowitz to L. Stevens; Attaching evaluations		
D0541	03/27/03		Cover Fax from L. Stevens to M. Brown re: Dr. Wolkowitz		
D0542	03/27/03		Letter from J. Lemieux to M. Jensen [no subject]; Attaching all of the documents in GSK's possession regarding the supplements to Physician Money Digest (Letter of Agreement dated 04/24/02, March 2002 Issue Receipt of Evaluation Forms dated 03/02, Information, Attaching January 11-14, 2000 Tentative Schedule of Events; January 12, 2001 Serotonin Special Issues Board		
D0543	03/28/03	8:49 AM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: FW: FW: SIB Information, Attaching January 11-14, 2000 Tentative Schedule of Events; January 12, 2001 Serotonin Special Issues Board		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0544	04/01/03	6:51 PM	Email from L. Stevens to M. Brown, M. Jensen, N. Reeves, ccd J. Lemieux, S. Shade re: [no subject]. Attaching "Completed spreadsheet for WLBCTRS75 exchange project.msg"		
D0545	04/01/03	7:07 PM	Email from N. Reeves to L. Stevens, M. Brown, M. Jensen, ccd to J. Lemieux, S. Shade, D. Clark re: RE: [no subject]		
D0546	04/02/03	11:47 AM	Email from L. Stevens to M. Brown, ccd to S. Shade, J. Lemieux, J. Hetzel, D. Snyder re: RE: Conf. Call		
D0547	04/02/03	11:52 AM	Email from D. Snyder to L. Stevens, ccd to M. Brown, S. Shade, J. Lemieux, J. Hetzel re: RE: Conf. Call		
D0548	04/02/03	12:15 PM	Email from M. Brown to L. Stevens, ccd to J. Hetzel, M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder re: RE: Conf. Call		
D0549	04/03/03		Memorandum from N. Reeves to L. Stevens, S. Shade re: Wellbutrin Slide Presentation Provided by Dr. Wolkowitz (without attachment)		
D0550	04/10/03	11:12 AM	Email from J. Lemieux to N. Reeves, L. Stevens, S. Shade, ccd to M. Jensen, M. Brown, J. Lang re: RE: Request for Information Needed to Track RMS-trained Physician Speaking. Attaching RMS-trained physician spreadsheet		
D0551	04/10/03	1:29 PM	Email from D. Snyder to L. Stevens, ccd to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: GSK's Supplemental Response to Question No. Attaching GSK's Supplemental Response to Question No. 14 (with blackline)		
D0552	04/10/03	5:50 PM	Email from L. Stevens to M. Brown, M. Jensen, N. Reeves, ccd to J. Lemieux, S. Shade re: [no subject]		
D0553	04/10/03	7:47 PM	Email from N. Reeves to J. Lemieux, L. Stevens, S. Shade, ccd to M. Jensen, M. Brown, J. Lang re: RE: Request for Information Needed to Track RMS-trained Physician Speaking		
D0554	04/16/03	2:45 PM	Email from N. Reeves to L. Stevens, S. Shade, J. Lemieux, ccd to M. Brown, M. Jensen re: FW: RMS-trained physicians. Attaching memorandum from J. Lang to M. Brown, M. Jensen, N. Reeves re: Number of times RMS-trained physicians spoke		
D0555	04/22/03	10:40 PM	Email from M. Brown to L. Stevens, D. Snyder, S. Shade, ccd to N. Reeves, M. Jensen re: WBSR: revised Wolkowitz narrative attached for your review. Attaching draft Wolkowitz narrative		
D0556	04/22/03		Letter from J. Lemieux to M. Jensen		
D0557	04/24/03	8:10 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: [no subject]		
D0558	04/30/03		Letter from J. Lemieux to M. Jensen [no subject]. Attaching fax from J. Quezada to L. Stevens re: July 17 2002 Pride Program, Attaching Three Hour Sales Call Planning Form, Dal Bufo invitation dated 07/17/02, Dal Bufo catering order form dated		
D0559	05/02/03	8:57 AM	Email from L. Stevens to M. Brown, D. Snyder, ccd to M. Jensen, J. Hetzel, J. Lemieux, N. Reeves, S. Shade re: Arrange Meeting		
D0560	05/22/03	8:15 AM	Email from L. Stevens to D. Snyder, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade re: [no subject]		
D0561	05/29/03	2:39 PM	Email from L. Stevens to J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder (no subject line, with handwriting)		
D0562	06/16/03	10:26 AM	Email from L. Stevens to M. Jensen, ccd to M. Brown, N. Reeves, D. Snyder, S. Shade, J. Lemieux, J. Hetzel re: RE: Draft Responses to Potential FDA Conf. Call Questions (with handwritten note)	RE: 6/20/11	RE: 6/20/11
D0563	09/02/03	4:01 PM	Email from L. Stevens to T. Thelen, C. Grant, S. Shade, M. Brown, D. Snyder re: Aldo Davico & Wellbutrin Investigation		
D0564	09/05/03	1:06 PM	Email from L. Stevens to C. Grant, M. Brown, S. Shade, T. Thelen, M. Brown re: FW: Davico: Attaching letter from D. Force to L. Stevens containing Written Statement of Employee by A. Davico		
D0565	09/05/03	1:06 PM	Email from L. Stevens to C. Grant, M. Brown, S. Shade, T. Thelen, M. Brown re: FW: Davico: Attaching letter from D. Force to L. Stevens containing written Statement of Employee by A. Davico		
D0566	09/05/03	1:06 PM	Email from L. Stevens to C. Grant, M. Brown, S. Shade, T. Thelen, M. Brown re: FW: Davico: Attaching letter from D. Force to L. Stevens re: Aldo Davico, Jr. Allegations of Off-label Promotions (with handwriting), email from M. Brown to M. Jensen, N.		
D0567	09/05/03	2:49 PM	E-mail from L. Stevens to M. Brown, M. Jensen, N. Reeves, S. Shade, D. Snyder, A. Carter, C. Grant and T. Thelen re: [no subject]		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0568	09/09/03	4:59 PM	Email from L. Stevens to C. Grant, C. Adrianna, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: PRIVILEGED & CONFIDENTIAL.		
D0569	09/10/03	1:26 PM	Email from L. Stevens to R. Arjun, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: Also Davico		
D0570	09/11/03	9:56 AM	Email from L. Stevens to D. Snyder, M. Jensen, M. Brown, N. Reeves, S. Shade, T. Thelen re: Also Davico. Attaching Memorandum from A. Davico to J. Lamb, dated 08/03/03. Letter from L. Shoenfelt to H. Rogers re: Aldo Davico, Jr. vs.		
D0571	09/11/03	9:57 AM	Email from L. Stevens to T. Thelen, N. Reeves, M. Jensen, M. Brown, S. Shade, D. Snyder re: Also [sic] Davico (with handwriting)		
D0572	09/11/03	9:57 AM	Email from L. Stevens to T. Thelen, N. Reeves, M. Jensen, M. Brown, S. Shade, D. Snyder re: Also [sic] Davico. Attaching 6/9/03 Letter from A. Davico to E. Hu of FDA re: Off-label promotion of WellbutrinSR by GlaxoSmithKline. 8/7/03 Letter from		
D0573	09/11/03	9:57 AM	Email from L. Stevens to T. Thelen, N. Reeves, M. Jensen, M. Brown, S. Shade, D. Snyder re: Also Davico. Attaching 6/9/03 Letter from A. Davico to E. Hu of FDA re: Off-label promotion of WellbutrinSR by GlaxoSmithKline		
D0574	09/12/03	9:23 AM	Email from L. Stevens to J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: [no subject]		
D0575	09/12/03	9:51 AM	Email from L. Stevens to M. Brown (no subject and with highlighting)		
D0576	09/12/03	9:51 AM	Email from L. Stevens to M. Brown re: [no subject]		
D0577	09/16/03	4:00 PM	Fax from L. Stevens to M. Brown. Attaching computer printouts (with handwriting)		
D0578	09/16/03	4:56 PM	Email from M. Brown to L. Stevens, ccd to N. Reeves re: Fax Earlier Today		
D0579	09/16/03	5:49 PM	Email from L. Stevens to M. Brown, ccd to N. Reeves, S. Shade, T. Thelen, D. Snyder, M. Jensen, J. Lemieux re: RE: Fax Earlier Today (with handwriting)		
D0580	09/17/03	10:18 AM	Email from M. Brown to L. Stevens, ccd to M. Jensen, J. Lemieux, N. Reeves, S. Shade, D. Snyder, T. Thelen re: Fax Earlier Today		
D0581	09/17/03	11:18 AM	Email from L. Stevens to M. Brown, ccd to N. Reeves, S. Shade, T. Thelen, D. Snyder, M. Jensen, J. Lemieux re: RE: Fax Earlier Today		
D0582	09/17/03	11:32 AM	Email from L. Stevens to N. Reeves, M. Brown, M. Jensen, ccd to S. Shade, J. Lemieux re: privileged/confidential legal communication		
D0583	09/17/03	11:42 AM	Fax from L. Stevens to M. Brown (no subject, with handwriting). Attaching Aldo Davico's non-PRIDE speaker events for 2001-3		
D0584	09/17/03	11:49 AM	Email from N. Reeves to L. Stevens, M. Brown, M. Jensen, ccd to S. Shade, J. Lemieux re: RE: privileged/confidential legal communication (without attachments)		
D0585	09/17/03	2:45 PM	Fax from S. Shade to M. Brown and N. Reeves. Attaching "The Theoretical Role of Norepinephrine and Dopamine in Human Behavior" PowerPoint presentation		
D0586	09/17/03	2:56 PM	Fax cover sheet and confirmation page from S. Shade to M. Brown, N. Reeves re: charts		
D0587	09/17/03		Fax from M. Brown to K. Stevens, Attaching Aldo Davico's speaker events (without attachment)		
D0588	09/17/03		Fax from L. Stevens to M. Brown. Attaching 9/17/03 11:32 a.m. Email from L. Stevens to N. Reeves, M. Brown, M. Jensen, ccd to S. Shade, J. Lemieux re: privileged/confidential legal communication. Attaching Speaker Event Program Activity for Rep		
D0589	09/23/03	8:09 AM	Email from L. Stevens to S. Shade, N. Reeves, M. Brown, ccd to J. Lemieux re: FW: Meeting with Aldo last Friday		
D0590	09/23/03	3:13 PM	Email from N. Reeves to L. Stevens, ccd to M. Brown re: GSK WBSR. Aldo Davico interview memo and attachments. Attaching September 23, 2003 Aldo Davico Interview Summary		
D0591	09/23/03	3:13 PM	Email from N. Reeves to L. Stevens, ccd to M. Brown re: GSK WBSR. Aldo Davico interview memo and attachments. Attaching Attachments D and E		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0592	09/23/03	4:20 PM	Email from N. Reeves to L. Stevens, ccd to M. Brown re: GSK WBSR. Aldo Davico interview memo and attachments.		
D0593	09/29/03	1:53 PM	Attaching Interview Memorandum and attachments A-E Email from S. Shade to M. Brown, N. Reeves, ccd to L. Stevens, D. Snyder re: [no subject]; Attaching Requests from Aldo Davico January 2001-December 2002		
D0594	09/30/03	7:58 AM	Email from L. Stevens to J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: FW: Management Change; Attaching 10/1/03 memorandum from J. Lamb to A. Davico, ccd to I. Acosta, C. Stellings		
D0595	09/30/03	7:58 AM	Email from L. Stevens to J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: FW: Management Change; Attaching 9/29/03 Memo from J. Lamb to A. Davico, ccd to I. Acosta, C. Stellings re: [no subject]		
D0596	09/30/03	10:45 AM	Email from M. Brown to N. Reeves, S. Shade, S. Stevens, ccd to D. Snyder re: [no subject]		
D0597	09/30/03	11:37 AM	Email from L. Stevens to M. Brown, N. Reeves, S. Shade, ccd to D. Snyder, J. Lemieux, T. Thelen re: RE		
D0598	10/01/03	7:34 AM	Email from L. Stevens to J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: FW: Management Change		
D0599	10/01/03	7:35 AM	Email from L. Stevens to J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder, T. Thelen re: FW: Management Change; Attaching 9/29/03 Memo from J. Lamb to A. Davico, ccd to I. Acosta, C. Stellings re: [no subject]		
D0600	10/03/03	9:51 AM	Email from T. Thelen to L. Stevens, J. Lemieux, M. Jensen, M. Brown, N. Reeves, S. Shade, D. Snyder re: RE: Management Change		
D0601	10/03/03	10:43 AM	Email from M. Brown to T. Thelen, L. Stevens, J. Lemieux, M. Jensen, N. Reeves, S. Shade, D. Snyder re: RE: Management Change		
D0602	10/03/03	10:51 AM	Email from T. Thelen to M. Brown, L. Stevens, J. Lemieux, M. Jensen, N. Reeves, S. Shade, D. Snyder re: RE: Management Change		
D0603	10/03/03	2:11 PM	Email from M. Brown to L. Stevens, S. Shade, D. Snyder, T. Thelen re: FW: Aldo Davico, Jr additional materials; Attaching Treatment Options for Primary Care PowerPoint		
D0604	10/07/03	10:08 AM	Email from L. Stevens to N. Reeves, M. Brown re: FW: James Saboye (with handwriting)		
D0605	10/07/03	10:08 AM	Email from L. Stevens to N. Reeves, M. Brown re: FW: James Saboye		
D0606	10/07/03	6:02 PM	Email from L. Stevens to N. Reeves re: FW: (with handwriting)		
D0607	10/07/03	6:02 PM	Email from L. Stevens to N. Reeves re: FW: [no subject]		
D0608	10/08/03	11:32 AM	Email from L. Stevens to N. Reeves re: FW: James Saboye (with handwriting)		
D0609	10/08/03	11:32 AM	Email from L. Stevens to N. Reeves re: FW: James Saboye		
D0610	10/10/03	4:00 PM	Email from L. Stevens to N. Reeves, ccd to S. Shade, M. Brown re: RE: [no subject]		
D0611	10/15/03	1:57 PM	Email from M. Brown to L. Stevens, S. Shade, ccd to N. Reeves re: Davico; Attaching 10/9/93 Letter from D. Force to M. Brown, K. N. Reeves re: Aldo Davico Jr and GSK		
D0612	10/15/03	3:06 PM	Email from L. Stevens to M. Brown, S. Shade, T. Thelen, ccd to N. Reeves re: RE: Davico		
D0613	10/15/03	3:14 PM	Email from J. Lemieux to M. Brown re: FW: Research for Jill and Jim		
D0614	10/16/03	6:59 PM	Email from N. Reeves to L. Stevens, ccd to M. Brown re: James Saboye interview memo attached		
D0615	10/17/03	7:56 AM	Email from L. Stevens to N. Reeves re: PRIVILEGED/CONFIDENTIAL; Attaching GSK Code of Conduct		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0616	10/19/03	9:06 AM	Email from L. Stevens to N. Reeves, M. Brown, S. Shade, J. Lemieux re: FW: Hudziak Tele. Attaching "The Theoretical Role of Norepinephrine and Dopamine in Human Behavior" PowerPoint presentation		
D0617	10/19/03	9:06 AM	Email from L. Stevens to N. Reeves, M. Brown, S. Shade, J. Lemieux re: FW: Hudziak Tele. Attaching "The Theoretical Role of Norepinephrine and Dopamine in Human Behavior" slides by J. Hudziak		
D0618	10/19/03	9:08 AM	Email from L. Stevens to N. Reeves, M. Brown, S. Shade, J. Lemieux re: FW: Program invitations. Attaching presentation invitations (with handwriting) dated 10/29/02		
D0619	10/19/03	9:14 AM	Email from L. Stevens to S. Shade, N. Reeves, M. Brown, J. Lemieux re: FW: Above and beyond award (without attachments)		
D0620	10/19/03	9:16 AM	Email from L. Stevens to J. Lemieux, N. Reeves, M. Brown, S. Shade re: FW: prior authorization for dinner w/ client		
D0621	10/19/03	9:08 PM	Email from L. Stevens to N. Reeves, M. Brown, S. Shade, J. Lemieux re: FW: Program invitations. Attaching Wellbutrin program draft		
D0622	10/20/03	2:09 PM	Fax from L. Stevens to N. Reeves (without attachment)		
D0623	10/21/03	4:06 PM	Email from L. Stevens to N. Reeves, M. Brown ccd to S. Shade, J. Lemieux re: FW: Davico's Training. Attaching transcript for Aldo Davico "Learning Activities in Progress", "Learning Activities Completed"		
D0624	10/21/03	5:29 PM	Email from M. Brown to N. Reeves, L. Stevens, ccd to S. Shade, J. Lemieux re: RE: Davico's Training		
D0625	10/22/03	11:25 AM	Email from L. Stevens to N. Reeves, M. Brown, ccd to S. Shade, S. Belinda, T. Thelen, re: PRIVILEGED/CONFIDENTIAL.		
D0626	10/22/03	11:25 AM	Email from L. Stevens to N. Reeves, M. Brown, S. Shade, B. Shannon, T. Thelen re: PRIVILEGED/CONFIDENTIAL. Attaching draft letter from M. Brown to D. Force re: Aldo Davico		
D0627	10/22/03	4:16 PM	Email from L. Stevens to M. Brown, B. Shannon, ccd to T. Thelen re: FW: Expense Report Correction		
D0628	10/23/03	5:58 PM	Email from N. Reeves to L. Stevens, ccd to M. Brown re: FW: Digital Sender Document. Attaching 10/22/03 letter from M. Brown to D. Force re: Aldo Davico		
D0629	10/27/03	10:02 AM	Email from L. Stevens to M. Brown, N. Reeves, ccd to J. Lemieux, S. Shade re: FW: Questions on PRIDE Utilization		
D0630	10/27/03	11:02 AM	Email from L. Stevens to M. Brown, N. Reeves, ccd to J. Lemieux, S. Shade, re: FW: Questions on PRIDE Utilization. Attaching spreadsheets		
D0631	10/31/03	9:22 AM	Email from M. Brown to S. Shade, N. Reeves, ccd to L. Stevens, J. Lemieux, T. Thelen re: RE: Draft Letter		
D0632	10/31/03	9:42 AM	Email from S. Shade to M. Brown, N. Reeves, ccd to L. Stevens, J. Lemieux, T. Thelen re: RE: Draft Letter		
D0633	10/31/03	9:46 AM	Email from M. Brown to S. Shade, ccd to L. Stevens, J. Lemieux, T. Thelen, N. Reeves re: RE: Draft Letter		
D0634	10/31/03	9:55 AM	Email from S. Shade to M. Brown, ccd to L. Stevens, J. Lemieux, T. Thelen, N. Reeves re: RE: Draft Letter (with handwriting)		
D0635	10/31/03	12:57 PM	Email from S. Shade to D. Snyder, M. Brown, N. Reeves, ccd to J. Lemieux, L. Stevens re: Draft Letter		
D0636	10/31/03	2:03 PM	Email from M. Brown to N. Reeves, S. Shade, D. Snyder, ccd to J. Lemieux, L. Stevens re: RE: Draft Letter		
D0637	11/05/03	4:10 PM	Email from L. Stevens to R. Whitlock-Smith, S. Shade, J. Lemieux, T. Thelen, M. Brown, D. Snyder re: FW: Aldo Davico		
D0638	11/05/03	5:20 PM	Email from S. Shade to M. Brown re: RE: Comments/Edits to Letter		
D0639	11/05/03	5:29 PM	Email from M. Brown to S. Shade re: RE: Comments/Edits to Letter		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0640	11/19/03		Signed letter from Julie Lemieux to M. Jensen re: Wellbutrin SR (bupropion HCl) Sustained-Release Tablets MACMIS # 11170		
D0641	12/22/03	5:03 PM	Email from N. Reeves to L. Stevens, cc'd to M. Brown, M. Jensen re: GSK WBSR: memo summarizing GSK response FDA inquiry into Wellbutrin SR promotion attached. Attaching memorandum from M. Brown, N. Reeves to L. Stevens re: Summary		
D0642	01/29/04	4:09 PM	Email from S. Shade to L. Stevens and J. Lemieux re: RE: Trained Speakers		
D0643	03/06/06	10:49 AM	Email from M. Brown to S. Shade, M. Jensen, N. Reeves, cc'd to L. Stevens, J. Lemieux re: RE: 2253 submissions of WBSR		
D0644	11/11/07		Fax from N. Reeves to L. Stevens, S. Shade, D. Snyder (no subject, without attachment)		
D0645	11/20/11	7:38 PM	Email from L. Stevens to D. Hanley, J. Hetzel, J. Lemieux, M. Jensen, M. Brown, S. Shade, D. Snyder, T. Thelen re: November 11, 2002. Attaching letter from L. Stevens to D. Ryan re: FDA Inquiry Of GlaxoSmithKline		
D0646			Fax from M. Brown to L. Stevens faxing Dr. Jim Anderson's roundtable discussion/dinner		
D0647			Email from Julie Lemieux to M. Brown, M. Jensen, N. Reeves re: RE: Speaker Utilization		
D0648			Email from J. Lemieux to M. Brown, M. Jensen, N. Reeves, cc'd to L. Stevens, S. Shade, re: RE: Speaker Utilization (with handwritten notes)		
D0649			Email from J. Lemieux to L. Stevens, M. Jensen, M. Brown, N. Reeves re: Trained Speakers (with handwritten notes)		
D0650			Print out from GlaxoSmithKline website homepage	MAY 3 2011	MAY 3 2011
D0700 01 - 700.6; 700.48 - 700.356; 700.360 700.569; 700.577 - 700.589; 700.797 -			Various documents from J. Lemieux's hard copy files sent to King & Spalding (Approximately Four Hard Copy Boxes)		
D0701			Lauren Stevens' Calendar Items		
D0702	08/15/72		37 Fed Reg 16503 - Legal Status of Approved Labeling for Prescription Drugs		
D0703	06/09/83		48 Fed Reg 26720 - Proposed New Drug, Antibiotic, and Biologic Drug Product Regulations		
D0704	10/01/90		Unlabeled Uses of Approved Drugs by Stuart L. Nighingale, MD (October 22-23, 1990)		
D0705	10/14/92		Remarks by David A. Kessler at the Annual Meeting of the American Academy of Pediatrics		
D0706	11/18/94		Federal Register, Volume 59 Issue 222 - Citizen Petition Regarding FDA Policy on Promotion of Unapproved Uses of Approved Drugs and Devices		
D0707	02/22/96		Statement of William B. Schultz - Promotion of Unapproved Drugs and Medical Devices		
D0708	09/12/96		Testimony on Supplemental Indications for Approved Prescription Drugs by Michael Friedman		
D0709	09/12/96		Off-Label Drug Use and FDA Review of Supplemental Drug Applications - Hearing Before the Subcommittee on Human Resources and Intergovernmental Relations		
D0710	01/01/97		FDA Guidance on Industry-Supported Scientific and Educational Activities (1997)		
D0711	01/01/97		1997 Annual Meeting of the American Medical Association - Reports of the Council on Scientific Affairs		
D0712	01/01/00		American Psychiatric Association's Practice Guidelines of Patients With Major Depressive Disorder (2000)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0713	01/01/01		Physicians' Perceptions and Uses of Commercial Drug Information Sources: An Examination of Pharmaceutical Marketing to Physicians by Lisa D. Spiller, PhD		
D0714	01/28/02		Letter from M. Dotzel to D. Popeo Re: Docket No. 01P-0250		
D0715	05/01/02		The Rationale for Off-Label Prescriptions (Health Affr 50, May 2000)		
D0716	07/01/02		American Academy of Pediatrics, Committee on Drugs - Uses of Drugs Not Described in the Package Insert (Off-Label Uses) (Pediatrics Vol. 110 No. 1 July 2002)		
D0717	01/01/03		Off-Label or Out of Bounds? Prescriber and Marketer Liability for Unapproved Uses of FDA-Approved Drugs by James O'Reilly and Amy Dalt (2003)		
D0718	01/01/06		2006 American Medical Association - Off-Label Prescribing Among Office-Based Physicians		
D0719	01/15/07		Science - Health Care Policy - Reforming Off-Label Promotion to Enhance Orphan Disease Treatment		
D0720	02/21/07		Medical News & Perspectives - Experts Weigh in on Promotion, Prescription of Off-Label Drugs		
D0721	01/01/09		FDA Guidance on Good Reprint Practices (2009)		
D0722	01/13/09		74 Fed Reg 1694 - Guidance on Good Reprint Practices		
D0723	01/01/10		American Psychiatric Association's Practice Guidelines of Patients With Major Depressive Disorder (2010)		
D0724	03/14/11		American Cancer Society Off-Label Drug Use		
D0725	04/03/11		The Independent Institute - Do Off-Label Drug Practices Argue Against FDA Efficacy Requirements? Testing an Argument by Structured Conversations		
D0726	06/03/11		Pediatric Drug Testing Enters Infancy by Janette Restivo, New York		
D0727	00/00/03		Dosing of Atypical Antipsychotics in Children and Adolescents		
D0728	00/00/08		Food and Drug Law and Regulation - FDA Regulation of Healthcare Professionals		
D0729	00/00/08		Food and Drug Law and Regulation - FDA Enforcement Powers		
D0730	00/00/08		Food and Drug Law and Regulation - Prescription Drug Promotion and Marketing		
D0731	00/00/98		FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions		
D0732	01/00/09		FDA Guidance, Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices		
D0733	06/00/76		The Philosophy of Enforcement		
D0734	07/00/08		GAO Report - FDA's Oversight of the Promotion of Drugs for Off-Label Uses		
D0735	08/00/08		House Report on FDA Career Staff Objected to Agency Preemption Policies		
D0736	09/00/99		Maker of Growth Hormone Feels Long Arm of the Law Article		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0737			Resume for Richard M. Cooper		
D0738			Off-label Drugs - Reimbursement Policies Constrain Physicians in Their Choice of Cancer Therapies		
D0739			Prescription Drugs - Implications of Drug Labeling and Off-label Use		
D0740			H-120,988 Patient Access to Treatments Prescribed by Their Physicians		
D0741			Regulatory Procedures Manual, Section 4-1 Warning Letters		
D0742			Regulatory Procedures Manual, Section 4-2 Unlabeled Letters		
D0743			Objective Slide		
D0744			Data sets used to determine Wellbutrin's use in obesity slide		
D0745			Percent of Wellbutrin use with evidence of obesity slide		
D0746			Share of uses for obesity, 2001-2002 - Employer claims data slide		
D0747			Share of uses for obesity, 2001-2002 - New Jersey Medicaid claims data slide		
D0748			Share of uses for obesity, 2001-2002 - PDDA data slide		
D0749			Share of uses for obesity, 2001-2002 - NDTI data slide		
D0750			Share of patients with obesity but without depression among users of antidepressants, 2001-2002 - MEPS data slide		
D0751			Share of all Wellbutrin uses by condition - PDPA data slide		
D0752			Share of all Wellbutrin uses by condition - NDTI data slide		
D0753			Share of all Wellbutrin uses by condition - PDPA data slide		
D0754			Share of all Wellbutrin uses by condition - NDTI data slide		
D0755			Share of Wellbutrin use for obesity across multiple data sources, 2001-2002		
D0800			Stevens handwritten notes (no image attached)		
D0801			Lemieux handwritten notes (no image attached)		
D0802			Hietzel handwritten notes (no image attached)		
D0803			Shade handwritten notes (no image attached)		
D0804			Reeves handwritten notes (no image attached)		

United States v. Stevens
Case No. 8:10-cr-00694
Defendant's Exhibit List

Exhibit No.	Date	Time	Description	Identification	Admitted
D0805			Jensen handwritten notes (no image attached)		
D0806			Brown handwritten notes (no image attached)		